KR20140123777A - Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same - Google Patents
Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same Download PDFInfo
- Publication number
- KR20140123777A KR20140123777A KR1020130041044A KR20130041044A KR20140123777A KR 20140123777 A KR20140123777 A KR 20140123777A KR 1020130041044 A KR1020130041044 A KR 1020130041044A KR 20130041044 A KR20130041044 A KR 20130041044A KR 20140123777 A KR20140123777 A KR 20140123777A
- Authority
- KR
- South Korea
- Prior art keywords
- genbank accession
- accession
- genbank
- gene
- methylation
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 건선 진단용 유전자 마커 및 이를 이용한 건선 진단방법에 관한 것으로서, 더 상세하게는 (a) 피험자의 생물학적 샘플로부터 서열번호 9의 염기서열로 표시되는 TP73 유전자, 서열번호 10의 염기서열로 표시되는 FANK1 유전자 및 서열번호 11의 염기서열로 표시되는 PPAPDC3 유전자로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현 수준 또는 메틸화 수준을 측정하는 단계; 및 (b) 상기 (a) 단계에서 측정한 유전자의 발현 수준 또는 메틸화 수준을 정상 대조군 샘플의 동일 유전자의 발현 수준 또는 메틸화 수준과 비교하는 단계를 포함하는 건선 진단에 필요한 정보를 제공하는 방법, TP73, FANK1 및 PPAPDC3로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 조성물 및 진단용 키트에 관한 것이다.
The present invention relates to a gene marker for psoriasis diagnosis and a method for diagnosing psoriasis using the same. More particularly, the present invention relates to (a) a TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9 from the biological sample of the subject, Measuring the expression level or methylation level of any one gene selected from the group consisting of the FANK1 gene and the PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: 11; And (b) comparing the expression level or the methylation level of the gene measured in the step (a) with an expression level or a methylation level of the same gene in a normal control sample, TP73 , FANK1, and PPAPDC3. The present invention also relates to a diagnostic kit and a kit for diagnosing psoriasis, which comprises an agent for measuring an expression level or a methylation level of a gene selected from the group consisting of FANK1 and PPAPDC3.
DNA 메틸화(DNA Methylation)는 유전자 발현의 조절기작 중의 하나로 DNA 염기서열을 Methyl기로 치환시켜서 DNA의 반응성을 낮추고 안정성을 높여서 유전자 발현을 억제하는 기작 중 하나이다. DNA는 처음 복제되었을 때에는 Methylation이 되어있지 않지만 복제 후에는 Methylation이 된다. DNA 메틸화는 DNA서열의 변동 없이 유전자의 불활성화를 초래하는 것으로 점 돌연변이, 유전자 결손 등의 유전자적 변화와 구분하여 후성학적 변화로 분류된다. DNA methylation is one of the mechanisms that regulate gene expression by replacing the DNA sequence with the Methyl group, thereby lowering the reactivity of the DNA and increasing its stability. DNA is not methylated when first cloned, but becomes methylation after cloning. DNA methylation results in inactivation of the gene without variation in the DNA sequence, which is classified as epigenetic change, distinguishing it from genetic changes such as point mutations and genetic defects.
최근 DNA 메틸화 측정을 통하여 암을 진단하는 방법들이 제시되고 있는데, DNA 메틸화는 주로 특정 유전자의 프로모터 부위의 CpG 섬(CpG island)의 시토신(cytosine)에서 일어나고, 그로 인하여 전사 인자의 결합이 방해를 받게 되어 특정 유전자의 전사가 차단되는 것으로서, 종양 억제 유전자의 프로모터 CpG 섬의 메틸화를 검색하는 것이 암 연구에 큰 도움이 되며, 이를 메틸화 특이 PCR(methylation specific PCR, 이하, "MSP"라고 함)이나 자동 염기 분석 등의 방법으로 검사하여 암의 진단과 스크리닝 등에 이용하려는 시도가 활발하게 이루어지고 있다.Recently, methods for diagnosing cancer through DNA methylation measurement have been proposed. DNA methylation occurs mainly in the cytosine of the CpG island (CpG island) of the promoter region of a specific gene, and thereby the binding of transcription factors is hindered And the methylation of the CpG island of the promoter of the tumor suppressor gene is highly useful for the cancer research. The methylation specific PCR (hereinafter referred to as "MSP ") or the automatic There have been active attempts to use such methods for the diagnosis and screening of cancer.
이는 프로모터 CpG 섬의 메틸화가 발암을 직접 유발하는지, 또는 발암에 2차적인 변화인지에 대한 논란이 있으나, 여러 암에서 종양 억제 유전자(tumor suppressor gene), DNA 수선 유전자(DNA repair gene), 세포 주기 조절 유전자 등이 과메틸화(hyper-methylation)되어 있어 이들 유전자의 발현이 차단되어 있다는 것이 확인되었으며, 특히 암 발생의 초기 단계에서 특정 유전자의 프로모터 부위에 과메틸화가 일어난다는 것이 밝혀졌다. 따라서, 종양관련 유전자의 프로모터 메틸화가 암의 중요한 지표로 인식되어, 실제 혈액이나 객담, 침, 대변, 소변 등에서 종양 관련 유전자의 프로모터 메틸화를 조사하여 각종 암 진료에 사용하려는 시도가 최근 활발하게 이루어지고 있다(Esteller, M. et al., Cancer Res., 59:67, 1999; Sanchez-Cespedez, M. et al., Cancer Res., 60:892, 2000; Ahlquist, D.A. et al., Gastroenterol., 119:1219, 2000). 그러나 다른 질환과 관련된 유전자의 프로모터 메틸화는 거의 연구되지 아니한 실정이며 특히 건선 환자에서 특이적으로 메틸레이션이 나타나는 유전자 프로모터 또는 이의 응용연구는 이루어진 바가 없다.It is controversial whether methylation of promoter CpG is directly inducing carcinogenesis or secondary changes in carcinogenesis. However, in many cancers, tumor suppressor gene, DNA repair gene, And hypermethylation of regulatory genes have been shown to block the expression of these genes. In particular, it has been shown that hypermethylation occurs at the promoter region of a specific gene at an early stage of cancer development. Therefore, the promoter methylation of the tumor-associated gene has been recognized as an important index of cancer, and an attempt has been actively made to investigate the promoter methylation of tumor-associated genes in actual blood, sputum, saliva, stool, Cancer Res., 60: 892, 2000; Ahlquist, DA et al., Gastroenterol., ≪ RTI ID = 0.0 > 119: 1219,2000). However, the promoter methylation of genes related to other diseases has not been studied so far. In particular, gene promoters with specific methylation in psoriasis patients or their application studies have not been studied.
건선(Psoriasis)은 피부에서 일어나는 만성 염증성 질병 중 하나로 두껍고 비늘 같은 각층이 생기는 것으로 특징을 갖고 있다. 건선의 병인은 아직 명확히 규명되지 않았으나, 다양한 증거들에 의해 활성화된 T 세포로부터 방출된 사이토카인(cytokines)이 케라티노사이트(keratinocytes)의 증식을 증진시키는, T-세포 매개된 염증성 질환인 것으로 보고 있다(Prinz, J.C. 등, 1997 및 Chang, J.C.C. 등, 1994). Psoriasis is a chronic inflammatory disease of the skin that is characterized by thick, scaly layers. Although the pathogenesis of psoriasis has not yet been clearly elucidated, cytokines released from T cells activated by various evidences have been reported to be T-cell mediated inflammatory diseases that promote keratinocytes proliferation (Prinz, JC et al., 1997 and Chang, JCC et al., 1994).
또한 건선의 발생에 유전적 요인이 관련되어 있음이 연구결과 밝혀져 있다. 환자의 약 1/3에서 가족력을 보이며, 일란성 쌍둥이에서 건선이 함께 발생할 확률이 이란성 쌍둥이에 비해 3배 이상 높다. 또한 가족 내에서 건선이 발생할 확률도 관련도(relatedness)와 비례한다는 점도 이를 뒷받침 하고 있다(Wuepper et al., J. Invest. Dermatol., 95: 2S-4S 1990).Studies have also shown that genetic factors are involved in the development of psoriasis. About one-third of patients have a family history, and the incidence of psoriasis in identical twins is three times higher than that of fraternal twins. In addition, the probability of psoriasis in the family is also in proportion to the relatedness (Wuepper et al., J. Invest. Dermatol., 95: 2S-4S 1990).
현재 건선의 치료는 증상을 일시적으로 완화시키는 연고나 또는 지속적 피부 관리를 유도하는 처방 등으로 사실상 근본적으로 치료는 시행되지 않고 있다. 스테로이드를 비롯한 건선 피부질환 치료제의 부작용을 고려하면, 이 질병들을 부작용 없이 근본적으로 치료할 수 있는 방법의 개발이 필요하며, 이를 위한 유전학적 표적 및 진단 방법의 개발이 필요하다.
Currently, the treatment of psoriasis, such as temporarily relieving the symptoms of ointment or prescription to induce persistent skin care, is actually not fundamentally treated. Considering the side effects of psoriasis skin disease drugs including steroids, it is necessary to develop a method that can radically treat these diseases without adverse effects, and development of genetic targets and diagnostic methods therefor is needed.
이에 본 발명자들은 건선 진단의 새로운 방법에 관하여 연구한 결과, 특정 유전자들의 메틸화 수준이 건선 환자가 정상인 대조군에 비하여 현저히 높은 것을 확인하여 본 발명을 완성하였다.
Accordingly, the inventors of the present invention conducted a study on a novel method for the diagnosis of psoriasis. As a result, the present inventors completed the present invention by confirming that the methylation level of specific genes is significantly higher than that of the control group in which psoriasis patients are normal.
따라서 본 발명의 목적은 (a) 피험자의 생물학적 샘플로부터 서열번호 9의 염기서열로 표시되는 TP73 유전자, 서열번호 10의 염기서열로 표시되는 FANK1 유전자 및 서열번호 11의 염기서열로 표시되는 PPAPDC3 유전자로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현 수준 또는 메틸화 수준을 측정하는 단계; 및 (b) 상기 (a) 단계에서 측정한 유전자의 발현 수준 또는 메틸화 수준을 정상 대조군 샘플의 동일 유전자의 발현 수준 또는 메틸화 수준과 비교하는 단계를 포함하는, 건선 진단에 필요한 정보를 제공하는 방법을 제공하는 것이다.
(A) a TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9, a FANK1 gene represented by the nucleotide sequence of SEQ ID NO: 10, and a PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: 11 from the biological sample of the subject Measuring an expression level or a methylation level of any one gene selected from the group consisting of And (b) comparing the expression level or the methylation level of the gene measured in step (a) with an expression level or methylation level of the same gene in a normal control sample. .
본 발명의 다른 목적은 서열번호 9의 염기서열로 표시되는 TP73 유전자, 서열번호 10의 염기서열로 표시되는 FANK1 유전자 및 서열번호 11의 염기서열로 ㅍ표표시되는 PPAPDC3 유전자로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 조성물을 제공하는 것이다.
Another object of the present invention is to provide a method for screening for a mutant gene selected from the group consisting of the TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9, the FANK1 gene represented by the nucleotide sequence of SEQ ID NO: 10, and the PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: Of the gene of the present invention or a methylation level thereof.
본 발명의 다른 목적은 서열번호 9의 염기서열로 표시되는 TP73 유전자, 서열번호 10의 염기서열로 표시되는 FANK1 유전자 및 서열번호 11의 염기서열로 표시되는 PPAPDC3 유전자로 이루어진 군에서 선택되는 어느 하나의 유전자 발현 수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 키트를 제공하는 것이다.
Another object of the present invention is to provide a method for screening for a mutation in a gene selected from the group consisting of the TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9, the FANK1 gene represented by the nucleotide sequence of SEQ ID NO: 10, and the PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: A gene expression level or a methylation level in a subject's body.
상기의 목적을 달성하기 위하여, 본 발명은 (a) 피험자의 생물학적 샘플로부터 TP73(서열번호 9 / GenBank Accession No. NM_001126240), FANK1 (서열번호 10 / GenBank Accession No. NM_145235) 및 PPAPDC3(서열번호 11 / GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현 수준 또는 메틸화 수준을 측정하는 단계; 및 (b) 상기 (a) 단계에서 측정한 유전자의 발현 수준 또는 메틸화 수준을 정상 대조군 샘플의 동일 유전자의 발현 수준 또는 메틸화 수준과 비교하는 단계를 포함하는, 건선 진단에 필요한 정보를 제공하는 방법을 제공한다.
(GenBank Accession No. NM_001126240), FANK1 (SEQ ID NO: 10 / GenBank Accession No. NM_145235), and PPAPDC3 (SEQ ID NO: 11) from a biological sample of a subject in order to achieve the above object. / GenBank Accession No. NM_032728), or a methylation level of a gene selected from the group consisting of: And (b) comparing the expression level or the methylation level of the gene measured in step (a) with an expression level or methylation level of the same gene in a normal control sample. to provide.
본 발명의 다른 목적을 달성하기 위하여, 본 발명은 TP73(서열번호 9 / GenBank Accession No. NM_001126240), FANK1 (서열번호 10 / GenBank Accession No. NM_145235) 및 PPAPDC3(서열번호 11 / GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 조성물을 제공한다.
(GenBank Accession No. NM_001126240), FANK1 (SEQ ID NO: 10 / GenBank Accession No. NM_145235) and PPAPDC3 (SEQ ID NO: 11 / GenBank Accession No. NM_032728 ) Or an expression level or a methylation level of any one gene selected from the group consisting of < RTI ID = 0.0 > a < / RTI >
본 발명의 다른 목적을 달성하기 위하여, 본 발명은 TP73(서열번호 9 / GenBank Accession No. NM_001126240), FANK1 (서열번호 10 / GenBank Accession No. NM_145235) 및 PPAPDC3(서열번호 11 / GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자 발현 수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 키트를 제공한다.
(GenBank Accession No. NM_001126240), FANK1 (SEQ ID NO: 10 / GenBank Accession No. NM_145235) and PPAPDC3 (SEQ ID NO: 11 / GenBank Accession No. NM_032728 ) Or an agent for measuring a gene expression level or a methylation level of a gene selected from the group consisting of: < RTI ID = 0.0 > a < / RTI >
이하 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 (a) 피험자의 생물학적 샘플로부터 TP73(서열번호 9 / GenBank Accession No. NM_001126240), FANK1 (서열번호 10 / GenBank Accession No. NM_145235) 및 PPAPDC3(서열번호 11 / GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현 수준 또는 메틸화 수준을 측정하는 단계; 및 (b) 상기 (a) 단계에서 측정한 유전자의 발현 수준 또는 메틸화 수준을 정상 대조군 샘플의 동일 유전자의 발현 수준 또는 메틸화 수준과 비교하는 단계를 포함하는, 건선 진단에 필요한 정보를 제공하는 방법을 제공한다.
The present invention relates to a method of screening for (a) a polypeptide comprising the amino acid sequence of TP73 (SEQ ID NO: 9 / GenBank Accession No. NM_001126240), FANK1 (SEQ ID NO: 10 / GenBank Accession No. NM_145235) and PPAPDC3 (SEQ ID NO: 11 / GenBank Accession No. NM_032728) Measuring an expression level or a methylation level of any one gene selected from the group consisting of And (b) comparing the expression level or the methylation level of the gene measured in step (a) with an expression level or methylation level of the same gene in a normal control sample. to provide.
본 발명에서 상기 유전자의 발현 수준은 유전자의 mRNA 또는 단백질 발현 수준을 측정하는 방법일 수 있고, 더 바람직하게는 mRNA 발현 측정일 수 있다.In the present invention, the expression level of the gene may be a method of measuring the mRNA or protein expression level of the gene, and more preferably the mRNA expression measurement.
상기 발현 수준을 측정하는 방법은 공지의 mRNA 또는 단백질 발현 수준 측정 방법 일 수 있고, 그 예로 RT-PCR, 경쟁적 RT-PCR(competitive RT-PCR), 실시간 RT-PCR(Real-time RT-PCR), RNase 보호 분석법(RPA:RNase protection assay), 노던 블랏팅(northern blotting), DNA 마이크로어레이 칩, 웨스턴 블럿팅(Western Blotting), 효소면역분석법(enzyme-linked immunosorbent assay), 방사능면역분석법(RIA), 방사면역확산법, 오우크테로니 면역 확산법, 로케트 면역 전기영동, 면역조직화학, 면역침전법(immunoprecipitation), 보체 고정 분석법, 유세포 분석법(FACS) 및 단백질 칩으로 이루어진 군에서 선택되는 하나 이상의 방법일 수 있고, 가장 바람직하게는 실시간 RT-PCR일 수 있다.
For example, RT-PCR, competitive RT-PCR, real-time RT-PCR, and the like can be used to measure the expression level. , RNase protection assay (RPA), northern blotting, DNA microarray chip, Western blotting, enzyme-linked immunosorbent assay, radioimmunoassay (RIA) , One or more methods selected from the group consisting of radioimmunoprecipitation, Ouchteroni immunodiffusion, rocket immunoelectrophoresis, immunohistochemistry, immunoprecipitation, complement fixation, flow cytometry (FACS) and protein chips. And most preferably real-time RT-PCR.
유전자의 메틸화는 DNA 서열의 변동 없이 유전자의 불활성화를 초래하는 것으로 점 돌연변이, 유전자 결손 등의 유전자적 변화와 구분하여 후성학적 변화로 분류된다. 메틸화 수준의 변화는 과메틸화(hypermethylation), 과소메틸화(hypomethylation)을 모두 포함하는 것이다. 메틸화 수준의 변화는 주로 암과 관련하여 연구가 진행되고 있으며, 건선과 관련되어 CD+ T 세포내 특이적으로 과메틸화 되는 유전자에 관하여는 알려진 바가 없다.The methylation of a gene results in inactivation of the gene without variation in the DNA sequence, which is classified as a postmenopausal change by distinguishing it from genetic changes such as point mutations and genetic defects. Changes in methylation levels include both hypermethylation and hypomethylation. Changes in the level of methylation are mainly studied in relation to cancer, and there is no known gene that specifically hypermethylated in CD + T cells associated with psoriasis.
상기 메틸화 수준을 측정하는 방법은 MIRA(methylated-CpG island recovery assay), PCR, 메틸화 특이 PCR(methylation specific PCR), 실시간 메틸화 특이 PCR(real time methylation specific PCR), 메틸화 DNA 특이적 결합 단백질을 이용한 PCR, 정량 PCR, 파이로시퀀싱 및 바이설파이트 시퀀싱으로 이루어진 군에서 선택된 하나 이상의 방법에 의해 측정되는 것을 특징으로 하는 방법일 수 있고, 가장 바람직하게는 MIRA 일 수 있다.
Methods for measuring the methylation level include MIRA (methylated-CpG island recovery assay), PCR, methylation specific PCR, real time methylation specific PCR, PCR using methylated DNA specific binding protein , Quantitative PCR, pyrosequencing, and bisulfite sequencing, and most preferably may be a MIRA.
진단은 병리 상태의 존재 또는 특징을 확인하는 것을 말하며, 본 발명의 진단은 건선의 발병여부를 확인하는 것을 말한다.Diagnosis refers to confirming the presence or characteristic of a pathological condition, and the diagnosis of the present invention refers to confirming whether or not psoriasis has occurred.
상기 생물학적 샘플은 혈액, 소변, 세포 및 조직으로 이루어진 군에서 선택되는 하나 이상인 것을 특징으로 한다. 상기 세포는 측정대상의 유전자를 분리할 수 있는 세포이면 어떤 것이나 가능하나, 바람직하게는 CD4+ T 세포 일 수 있다.The biological sample may be at least one selected from the group consisting of blood, urine, cells, and tissues. The cell may be any cell capable of separating a gene to be measured, preferably, it may be a CD4 + T cell.
본 발명에서 "CD4+ T 세포"는 naive CD4+ T cell, Th1(T helper type I), Th2(T helper type 2), T helper type 17(Th17), iTreg 세포를 모두 총칭한다. 본 출원인은 negative 선별로 상기 총 T 세포들을 수집하여 실험을 진행했다(실시예 1-2 참조). naive CD4+ cell은 주변의 사이토킨 농도에 의해 Th1, Th2, Th17, iTreg로 분화하게 된다. Th1세포의 경우, 인터페론-감마, 인터루킨-12 등의 사이토킨에 의해 분화되고, Th2 세포의 경우, 인터루킨-4,2 등에 의해 분화된다. 또한 Th17 세포는 TGF-β, IL-6, IL-21, IL-23 등의 사이토킨에 의해 분화되고, iTreg 세포는 TGF-β, IL-2에 의해 분화된다.
In the present invention, "CD4 + T cell" is collectively referred to as naive CD4 + T cell, Th1 (T helper type I), Th2 (T helper type 2), T helper type 17 (Th17) and iTreg cells. Applicants collected the total T cells by negative selection and conducted the experiment (see Example 1-2). naive CD4 + cells are differentiated into Th1, Th2, Th17, and iTreg by surrounding cytokine concentrations. In the case of Th1 cells, they are differentiated by cytokines such as interferon-gamma and interleukin-12, and in the case of Th2 cells, they are differentiated by interleukin-4,2. In addition, Th17 cells are differentiated by cytokines such as TGF-β, IL-6, IL-21 and IL-23, and iTreg cells are differentiated by TGF-β and IL-2.
TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 및 PPAPDC3(GenBank Accession No. NM_032728) 유전자들은 정상환자보다 건선환자에서 과메틸화 되는 유전자들이다(실시예 2-3 참조). 따라서 상기 유전자들의 메틸화 수준이 정상 대조군보다 높다면 건선으로 진단할 수 있다.The genes TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) and PPAPDC3 (GenBank Accession No. NM_032728) are genes that are hypermethylated in psoriasis patients than normal patients (see Example 2-3). Therefore, if the methylation level of the genes is higher than that of the normal control, it can be diagnosed as psoriasis.
본 발명인들은 건선 환자와 정상군 환자로부터 Total CD4+ T cell을 분리하여, 상기 세포로부터 genomic DNA를 분리한 후, 메틸화(methylation) 된 DNA 분획들을 선별하여, mapping을 시도한 후, genome-wide 수준, 유전자 단위 수준으로 과메틸화(hypermethylation) 된 유전자들을 선별하였다. genome-wide 수준 분석에서 발견된 과메틸화 유전자들은 [표 2]에, 유전자 단위 수준 분석에서 발견된 과메틸화 유전자들은 [표 3]에 기재하였다. The present inventors isolated total CD4 + T cells from patients with psoriasis and normal subjects, isolated genomic DNA from the cells, selected methylated DNA fragments, attempted mapping, Genes that were hypermethylated at the gene unit level were selected. The methylation genes found in the genome-wide level analysis are shown in [Table 2], and the methylation genes found in the gene unit level analysis are listed in [Table 3].
DNA 메틸화는 DNA methyl transferase(DNMT)에 의해 CpG의 5’탄소 부위에 메틸기(-CH3)가 결합된 것이다. CpG dinucleotides가 여러 개 모여있는 CpG islands는 주로 promoter나 근처에 또는 exon의 시작 부위에 위치하는데 CpG islands에 메틸기(methyl)가 결합하면, mRNA 전사가 방해를 받아서 유전자 발현이 억제된다(박일석, Korean J Otorhinolaryngol-Head Neck Surg;52:943-8,2009). 실제로 [표 2]와 [표 3]에 나열한 유전자들 중, 임의로 TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 및 PPAPDC3(GenBank Accession No. NM_032728) 유전자들을 선택하여, 이들의 mRNA 발현 수준을 측정해본 결과, 정상 환자군보다 mRNA 발현율이 현저히 낮았다. 메틸화를 억제하는 5-azacytidine를 건선 환자의 CD4+ T 세포에 처리하여, mRNA 발현을 측정한 결과, 5-azacytidine 비처리군에 비하여 발현율이 월등히 높아졌다. 즉, mRNA 발현을 억제하는 원인이 메틸화기작(methylation) 임을 확인할 수 있다(<실시예 3> 및 [도 3] 참조).DNA methylation is a DNA methyl transferase (DNMT) that binds a methyl group (-CH 3 ) to the 5 'carbon of CpG. CpG islands in which several CpG dinucleotides are clustered are located mainly at the promoter or at the beginning of the exon. When methyl is bonded to the CpG islands, mRNA transcription is interrupted and gene expression is suppressed (Park, Otorhinolaryngol-Head Neck Surg; 52: 943-8, 2009). Actually, genes TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) and PPAPDC3 (GenBank Accession No. NM_032728) are selected from among the genes listed in [Table 2] and [Table 3] As a result of measuring the level of mRNA expression, mRNA expression rate was significantly lower than that of normal patients. The expression of 5-azacytidine, an inhibitor of methylation, on CD4 + T cells of psoriatic patients and mRNA expression was significantly higher than that of the 5-azacytidine-untreated group. That is, it can be confirmed that methylation is the cause of inhibiting mRNA expression (Examples 3 and 3).
또한, 메틸화가 유전자 프로모터에서 일어나 그 활성을 억제하는지 여부를 유전자 TR73으로 실험한 결과, 메틸화가 프로모터의 활성을 감소시킨다는 것을 확인하였다(<실시예 4> 및 [도 4] 참조).Further, it was confirmed by the gene TR73 that methylation occurs in the gene promoter and inhibits its activity, and it was confirmed that methylation decreased the activity of the promoter (see Example 4 and Fig. 4).
따라서 정상 대조군 보다 TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 또는 PPAPDC3(GenBank Accession No. NM_032728) 유전자의 발현 수준이 낮다면, 건선으로 진단할 수 있다.
Therefore, if the expression level of TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) or PPAPDC3 (GenBank Accession No. NM_032728) gene is lower than that of normal control, it can be diagnosed as psoriasis.
또한, 상기 3가지 유전자 중 어느 하나 유전자 외에 하기 나열한 유전자 중 하나 이상의 유전자를 택하여 발현수준 또는 메틸화 수준을 측정하는 단계를 추가적으로 포함하는 것을 특징으로 한다. In addition, the method may further include the step of measuring the expression level or the methylation level by selecting one or more genes among the genes listed below in addition to any one of the three genes.
추가로 측정 대상이 되는 유전자로는 HOXA5(GenBank Accession No. NM_019102), TPTE (GenBank Accession No. NM_199260), SPESP1(GenBank Accession No. NM_145658), MIR200A(GenBank Accession No. NR_029834), NADK(GenBank Accession No. NM_001198995), LOC100130417(GenBank Accession No. NR_026874), MIR663B(GenBank Accession No. NR_031608), ANKRD30BL(GenBank Accession No. NR_027020), UCN(GenBank Accession No. NM_003353), LOC100130872(GenBank Accession No. NR_024569), SPON2(GenBank Accession No. NM_001199021), MIR1229(GenBank Accession No. NR_031598), C6orf201(GenBank Accession No. NM_001085401), MEST(GenBank Accession No. NM_002402), SOHLH1(GenBank Accession No. NM_001101677), SYCE1(GenBank Accession No. NM_001143763), ANKRD30A(GenBank Accession No. NM_052997), KCNQ1DN(GenBank Accession No. NR_024627), AGAP2(GenBank Accession No. NM_001122772), TDRD9(GenBank Accession No. NM_153046), FAM181A(GenBank Accession No. NM_001207074), KLHL33(GenBank Accession No. NM_001109997), REREP3(GenBank Accession No. NR_033735), NOX5(GenBank Accession No. NR_033671), NCRNA00273(GenBank Accession No. NR_038368), ALOX12(GenBank Accession No. NM_000697), MIR3187(GenBank Accession No. NR_036154), LOC100288123(GenBank Accession No. NR_034114), EXOC3L2(GenBank Accession No. NM_138568), MIR4745(GenBank Accession No. NR_039900), C19orf77(GenBank Accession No. NM_001136503), C19orf34(GenBank Accession No. NR_033400), MIR663(GenBank Accession No. NR_030386), C20orf177(GenBank Accession No. NM_001190826), GNAS(GenBank Accession No. NR_003259), TTLL10(GenBank Accession No. NM_153254), FAM132A(GenBank Accession No. NM_001014980), C1orf146(GenBank Accession No. NM_001012425), EIF2B3(GenBank Accession No. NM_020365), CCDC27(GenBank Accession No. NM_152492), CROCCL1(GenBank Accession No. NR_026752), FAM58B(GenBank Accession No. NM_001105517), TMEM61(GenBank Accession No. NM_182532), OBSCN(GenBank Accession No. NM_052843), OBSCN(GenBank Accession No. NM_001098623), GPR25(GenBank Accession No. NM_005298), C1orf170(GenBank Accession No. NR_027693), FGR(GenBank Accession No. NM_005248), HSPA7(GenBank Accession No. NR_024151), PER3(GenBank Accession No. NM_016831), CLDN19(GenBank Accession No. NM_001123395), MMEL1(GenBank Accession No. NM_033467), PLEKHN1(GenBank Accession No. NM_032129), GPR37L1(GenBank Accession No. NM_004767), SLC25A44(GenBank Accession No. NM_014655), ICMT(GenBank Accession No. NM_012405), KLF17(GenBank Accession No. NM_173484), AFARP1(GenBank Accession No. NR_002796), HIST3H3(GenBank Accession No. NM_003493), OR2L13(GenBank Accession No. NM_175911), PVRL4(GenBank Accession No. NM_030916), EPS8L3(GenBank Accession No. NM_139053), CLCNKA(GenBank Accession No. NM_004070), NCRNA00164(GenBank Accession No. NR_027020), UCN(GenBank Accession No. NM_003353), KRTCAP3(GenBank Accession No. NM_173853), NCRNA00164(GenBank Accession No. NR_027019), ANKMY1(GenBank Accession No. NM_016552), TEKT4(GenBank Accession No. NM_144705), LOC654433(GenBank Accession No. NR_015377), DNAJC5G(GenBank Accession No. NM_173650), C2orf54(GenBank Accession No. NM_001085437), ALPPL2(GenBank Accession No. NM_031313), KLHL30(GenBank Accession No. NM_198582), POTEF(GenBank Accession No. NM_001099771), BOLL(GenBank Accession No. NM_033030), RGPD4(GenBank Accession No. NM_182588), TUBA3D(GenBank Accession No. NM_080386), ARHGEF4(GenBank Accession No. NM_032995), RGPD3(GenBank Accession No. NM_001144013), CRYGA(GenBank Accession No. NM_014617), PRLH(GenBank Accession No. NM_015893), LOC401010(GenBank Accession No. NR_002826), MFSD2B(GenBank Accession No. NM_001080473), EMILIN1(GenBank Accession No. NM_007046), SCTR(GenBank Accession No. NM_002980), C2orf39(GenBank Accession No. NM_145038), NT5DC2(GenBank Accession No. NM_022908), PRR23C(GenBank Accession No. NM_001134657), ITIH4(GenBank Accession No. NM_002218), DPPA2(GenBank Accession No. NM_138815), RARRES1(GenBank Accession No. NM_206963), GRK7(GenBank Accession No. NM_139209), TM4SF19(GenBank Accession No. NM_138461), OSTalpha(GenBank Accession No. NM_152672), AMT(GenBank Accession No. NM_000481), PRSS50(GenBank Accession No. NM_013270), HTR3E(GenBank Accession No. NM_182589), EIF4E3(GenBank Accession No. NM_173359), PLXNA1(GenBank Accession No. NM_032242), DAZL(GenBank Accession No. NM_001351), PRR23A(GenBank Accession No. NM_001134659), SLC6A11(GenBank Accession No. NM_014229), PRSS42(GenBank Accession No. NM_182702), LOC100130872(GenBank Accession No. NR_024569), DCAF4L1(GenBank Accession No. NM_001029955), C4orf44(GenBank Accession No. NM_001042690), TRIM60(GenBank Accession No. NM_152620), FAM92A3(GenBank Accession No. NR_003612), ADAD1(GenBank Accession No. NM_139243), RBM46(GenBank Accession No. NM_144979), OTOP1(GenBank Accession No. NM_177998), SLC26A1(GenBank Accession No. NM_213613), RNF212(GenBank Accession No. NM_001131034), LOC650293(GenBank Accession No. NM_001040071), ZNF595(GenBank Accession No. NM_182524), FRG1(GenBank Accession No. NM_004477), YTHDC1(GenBank Accession No. NM_001031732), NAP1L5(GenBank Accession No. NM_153757), COX7B2(GenBank Accession No. NM_130902), FTMT(GenBank Accession No. NM_177478), LRRC14B(GenBank Accession No. NM_001080478), SLC25A2(GenBank Accession No. NM_031947), CMYA5(GenBank Accession No. NM_153610), SLC6A19(GenBank Accession No. NM_001003841), IL3(GenBank Accession No. NM_000588), C5orf47(GenBank Accession No. NM_001144954), DND1(GenBank Accession No. NM_194249), CDX1(GenBank Accession No. NM_001804), SLC45A2(GenBank Accession No. NM_016180), CDH9(GenBank Accession No. NM_016279), FAM170A(GenBank Accession No. NM_182761), PDLIM4(GenBank Accession No. NM_003687), PFN3(GenBank Accession No. NM_001029886), ZDHHC11(GenBank Accession No. NM_024786), LOC134466(GenBank Accession No. NR_026867), PPP1R2P3(GenBank Accession No. NR_002168), GMCL1L(GenBank Accession No. NR_003281), PLEKHG4B(GenBank Accession No. NM_052909), IRX2(GenBank Accession No. NM_033267), C6orf201(GenBank Accession No. NM_001085401), HIST1H1A(GenBank Accession No. NM_005325), DUSP22(GenBank Accession No. NM_020185), HDGFL1(GenBank Accession No. NM_138574), DDX43(GenBank Accession No. NM_018665), PLAGL1(GenBank Accession No. NM_006718), HIST1H4G(GenBank Accession No. NM_003547), DPPA5(GenBank Accession No. NM_001025290), FAM50B(GenBank Accession No. NM_012135), FRMD1(GenBank Accession No. NM_024919), PNLDC1(GenBank Accession No. NM_173516), TDRD6(GenBank Accession No. NM_001010870), HUS1B(GenBank Accession No. NM_148959), ID4(GenBank Accession No. NM_001546), MCART3P(GenBank Accession No. NR_026540), C6orf221(GenBank Accession No. NM_001017361), MEST(GenBank Accession No. NM_002402), BHLHA15(GenBank Accession No. NM_177455), NOBOX(GenBank Accession No. NM_001080413), HOXA4(GenBank Accession No. NM_002141), GPR146(GenBank Accession No. NM_138445), ZNF716(GenBank Accession No. NM_001159279), RAMP3(GenBank Accession No. NM_005856), AMZ1(GenBank Accession No. NM_133463), SGCE(GenBank Accession No. NM_001099401), ELFN1(GenBank Accession No. NM_001128636), CPA1(GenBank Accession No. NM_001868), AMAC1L2(GenBank Accession No. NM_054028), TSPYL5(GenBank Accession No. NM_033512), KIAA1875(GenBank Accession No. NR_024207), DCAF4L2(GenBank Accession No. NM_152418), SLC39A4(GenBank Accession No. NM_017767), HTRA4(GenBank Accession No. NM_153692), POTEA(GenBank Accession No. NM_001005365), PTP4A3(GenBank Accession No. NM_032611), CSMD3(GenBank Accession No. NM_198124), NRBP2(GenBank Accession No. NM_178564), LOC100130274(GenBank Accession No. NM_001162914), C8orf73(GenBank Accession No. NM_001100878), GPIHBP1(GenBank Accession No. NM_178172), LY6D(GenBank Accession No. NM_003695), GPT(GenBank Accession No. NM_005309), MAPK15(GenBank Accession No. NM_139021), LRRC24(GenBank Accession No. NM_001024678), RP1L1(GenBank Accession No. NM_178857), SLC45A4(GenBank Accession No. NM_001080431), SNX16(GenBank Accession No. NM_022133), SOHLH1(GenBank Accession No. NM_001012415), EGFL7(GenBank Accession No. NM_016215), PTGDS(GenBank Accession No. NM_000954), NPR2(GenBank Accession No. NM_003995), DBH(GenBank Accession No. NM_000787), NR5A1(GenBank Accession No. NM_004959), FAM166A(GenBank Accession No. NM_001001710), C9orf135(GenBank Accession No. NM_001010940), MAMDC4(GenBank Accession No. NM_206920), CARD9(GenBank Accession No. NM_052813), OR13J1(GenBank Accession No. NM_001004487), C9orf152(GenBank Accession No. NM_001012993), POMT1(GenBank Accession No. NM_001136113), TMC1(GenBank Accession No. NM_138691), CACNA1B(GenBank Accession No. NM_000718), PRKACG(GenBank Accession No. NM_002732), PAEP(GenBank Accession No. NM_001018049), S1PR3(GenBank Accession No. NM_005226), SNORD62A(GenBank Accession No. NR_002914), ANKRD30A(GenBank Accession No. NM_052997), C10orf116(GenBank Accession No. NM_006829), GPR26(GenBank Accession No. NM_153442), CTBP2(GenBank Accession No. NM_022802), CCNY(GenBank Accession No. NM_181698), PNLIPRP2(GenBank Accession No. NM_005396), PYROXD2(GenBank Accession No. NM_032709), GDF2(GenBank Accession No. NM_016204), MMP21(GenBank Accession No. NM_147191), CALML3(GenBank Accession No. NM_005185), JAKMIP3(GenBank Accession No. NM_001105521), ANKRD2(GenBank Accession No. NM_020349), C10orf108(GenBank Accession No. NR_027152), IDI2(GenBank Accession No. NM_033261), RBP3(GenBank Accession No. NM_002900), TUBB8(GenBank Accession No. NM_177987), TUBGCP2(GenBank Accession No. NM_006659), KCNQ1DN(GenBank Accession No. NR_024627), LOC441601(GenBank Accession No. NR_003034), SPDYC(GenBank Accession No. NM_001008778), CD248(GenBank Accession No. NM_020404), TSSC4(GenBank Accession No. NM_005706), H19(GenBank Accession No. NR_002196), LDHAL6A(GenBank Accession No. NM_144972), FOXR1(GenBank Accession No. NM_181721), PKP3(GenBank Accession No. NM_007183), MS4A15(GenBank Accession No. NM_001098835), MRGPRE(GenBank Accession No. NM_001039165), MUC6(GenBank Accession No. NM_005961), LSP1(GenBank Accession No. NM_002339), TNNT3(GenBank Accession No. NM_006757), TP53AIP1(GenBank Accession No. NM_022112), CATSPER1(GenBank Accession No. NM_053054), TAGLN(GenBank Accession No. NM_001001522), CABP2(GenBank Accession No. NM_016366), GNG3(GenBank Accession No. NM_012202), CEND1(GenBank Accession No. NM_016564), FOLR3(GenBank Accession No. NM_000804), TMEM218(GenBank Accession No. NM_001080546), TBX10(GenBank Accession No. NM_005995), SCGB2A1(GenBank Accession No. NM_002407), C11orf36(GenBank Accession No. NR_027138), DRD4(GenBank Accession No. NM_000797), MUC2(GenBank Accession No. NM_002457), AGAP2(GenBank Accession No. NM_001122772), RPL13AP20(GenBank Accession No. NR_003932), FIGNL2(GenBank Accession No. NM_001013690), ACRBP(GenBank Accession No. NM_032489), SLC6A12(GenBank Accession No. NM_003044), KRT3(GenBank Accession No. NM_057088), TUBGCP3(GenBank Accession No. NM_006322), SOHLH2(GenBank Accession No. NM_017826), ATP4B(GenBank Accession No. NM_000705), RNF17(GenBank Accession No. NM_031277), TUBA3C(GenBank Accession No. NM_006001), CSNK1A1L(GenBank Accession No. NM_145203), DLEU7(GenBank Accession No. NM_198989), TDRD9(GenBank Accession No. NM_153046), DIO3(GenBank Accession No. NM_001362), COX8C(GenBank Accession No. NM_182971), ASPG(GenBank Accession No. NM_001080464), MGC23270(GenBank Accession No. NR_024396), RPL13AP3(GenBank Accession No. NR_004844), RPS6KL1(GenBank Accession No. NM_031464), ACOT4(GenBank Accession No. NM_152331), CMTM5(GenBank Accession No. NM_138460), INF2(GenBank Accession No. NM_022489), AMN(GenBank Accession No. NM_030943), ABHD12B(GenBank Accession No. NM_181533), TBPL2(GenBank Accession No. NM_199047), PSMB11(GenBank Accession No. NM_001099780), CATSPER2(GenBank Accession No. NM_054020), LOC390594(GenBank Accession No. NM_001101362), C15orf2(GenBank Accession No. NM_018958), PCSK6(GenBank Accession No. NM_002570), C15orf60(GenBank Accession No. NM_001042367), SNORD115-6(GenBank Accession No. NR_003298), SNORD115-17(GenBank Accession No. NR_003309), RASL12(GenBank Accession No. NM_016563), SNORD115-32(GenBank Accession No. NR_003347), SNORD115-31(GenBank Accession No. NR_003346), LASS3(GenBank Accession No. NM_178842), SNORD115-37(GenBank Accession No. NR_003352), LDHAL6B(GenBank Accession No. NM_033195), GABRB3(GenBank Accession No. NM_000814), SNORD115-25(GenBank Accession No. NR_003342), SLC28A2(GenBank Accession No. NM_004212), ZNF469(GenBank Accession No. NM_001127464), CCDC154(GenBank Accession No. NM_001143980), TESSP1(GenBank Accession No. NM_001135086), ELMO3(GenBank Accession No. NM_024712), ZSCAN10(GenBank Accession No. NM_032805), PDIA2(GenBank Accession No. NM_006849), LOC146336(GenBank Accession No. NR_027242), CLDN9(GenBank Accession No. NM_020982), CLDN6(GenBank Accession No. NM_021195), IGFALS(GenBank Accession No. NM_001146006), IL34(GenBank Accession No. NM_152456), NAT15(GenBank Accession No. NM_001083601), SSTR5(GenBank Accession No. NM_001053), DNASE1L2(GenBank Accession No. NM_001374), MSLN(GenBank Accession No. NM_005823), CMTM1(GenBank Accession No. NM_052999), FBRS(GenBank Accession No. NM_001105079), ZNF597(GenBank Accession No. NM_152457), SLC5A11(GenBank Accession No. NM_052944), IL17C(GenBank Accession No. NM_013278), FAM18A(GenBank Accession No. NM_001079512), TPSG1(GenBank Accession No. NM_012467), GPR97(GenBank Accession No. NM_170776), PRM2(GenBank Accession No. NM_002762), JMJD8(GenBank Accession No. NM_001005920), ADAD2(GenBank Accession No. NM_139174), C16orf81(GenBank Accession No. NR_024347), TPSD1(GenBank Accession No. NM_012217), ADCY7(GenBank Accession No. NM_001114), ZG16B(GenBank Accession No. NM_145252), CHST5(GenBank Accession No. NM_024533), PRR25(GenBank Accession No. NM_001013638), ABCA3(GenBank Accession No. NM_001089), CCDC79(GenBank Accession No. NM_001136505), WDR59(GenBank Accession No. NM_030581), GLIS2(GenBank Accession No. NM_032575), MT1L(GenBank Accession No. NR_001447), TMPRSS8(GenBank Accession No. NR_026864), TMC7(GenBank Accession No. NM_024847), DNASE1(GenBank Accession No. NM_005223), ALOX12(GenBank Accession No. NM_000697), KCNAB3(GenBank Accession No. NM_004732), DYSFIP1(GenBank Accession No. NM_001007533), QRICH2(GenBank Accession No. NM_032134), FSCN2(GenBank Accession No. NM_012418), CACNG1(GenBank Accession No. NM_000727), TMEM88(GenBank Accession No. NM_203411), UTS2R(GenBank Accession No. NM_018949), HSPB9(GenBank Accession No. NM_033194), NLGN2(GenBank Accession No. NM_020795), FOXO3B(GenBank Accession No. NR_026718), FLJ36000(GenBank Accession No. NR_027084), RPH3AL(GenBank Accession No. NM_006987), GGT6(GenBank Accession No. NM_001122890), RAB34(GenBank Accession No. NM_031934), SHISA6(GenBank Accession No. NM_207386), GPR172B(GenBank Accession No. NM_001104577), SLFN13(GenBank Accession No. NM_144682), HSF5(GenBank Accession No. NM_001080439), ENPP7(GenBank Accession No. NM_178543), AIPL1(GenBank Accession No. NM_014336), AMAC1(GenBank Accession No. NM_152462), KCTD11(GenBank Accession No. NM_001002914), WSB1(GenBank Accession No. NM_015626), SERPINF1(GenBank Accession No. NM_002615), ULK2(GenBank Accession No. NM_014683), TBX4(GenBank Accession No. NM_018488), CCDC144NL(GenBank Accession No. NM_001004306), KCNG2(GenBank Accession No. NM_012283), RNF138(GenBank Accession No. NM_016271), ANKRD30B(GenBank Accession No. NM_001145029), PSMA8(GenBank Accession No. NM_144662), CNDP1(GenBank Accession No. NM_032649), EXOC3L2(GenBank Accession No. NM_138568), C19orf77(GenBank Accession No. NM_001136503), C19orf34(GenBank Accession No. NM_152771), FZR1(GenBank Accession No. NM_001136198), TMPRSS9(GenBank Accession No. NM_182973), ZNF558(GenBank Accession No. NM_144693), PLVAP(GenBank Accession No. NM_031310), YJEFN3(GenBank Accession No. NM_198537), CCDC155(GenBank Accession No. NM_144688), TMEM86B(GenBank Accession No. NM_173804), SPACA4(GenBank Accession No. NM_133498), PRR22(GenBank Accession No. NM_001134316), ELANE(GenBank Accession No. NM_001972), ACPT(GenBank Accession No. NM_033068), PSPN(GenBank Accession No. NM_004158), WDR88(GenBank Accession No. NM_173479), PLIN4(GenBank Accession No. NM_001080400), OR10H1(GenBank Accession No. NM_013940), CCDC105(GenBank Accession No. NM_173482), SNORD37(GenBank Accession No. NR_002602), DUS3L(GenBank Accession No. NM_020175), CBLC(GenBank Accession No. NM_012116), LGALS4(GenBank Accession No. NM_006149), COX7A1(GenBank Accession No. NM_001864), KCNA7(GenBank Accession No. NM_031886), NTN5(GenBank Accession No. NM_145807), SNORD35A(GenBank Accession No. NR_000018), FFAR2(GenBank Accession No. NM_005306), ZSCAN1(GenBank Accession No. NM_182572), LOC126536(GenBank Accession No. NR_026828), LYPD4(GenBank Accession No. NM_173506), DMRTC2(GenBank Accession No. NM_001040283), ACTL9(GenBank Accession No. NM_178525), TDRD12(GenBank Accession No. NM_001110822), CAPS(GenBank Accession No. NM_004058), PGLYRP1(GenBank Accession No. NM_005091), CAPN12(GenBank Accession No. NM_144691), FAM83E(GenBank Accession No. NM_017708), NLRP4(GenBank Accession No. NM_134444), PPAP2C(GenBank Accession No. NM_003712), UPK1A(GenBank Accession No. NM_007000), INSL3(GenBank Accession No. NM_005543), KCNJ14(GenBank Accession No. NM_170720), ODF3L2(GenBank Accession No. NM_182577), PLK5P(GenBank Accession No. NR_026557), AURKC(GenBank Accession No. NM_001015878), ECH1(GenBank Accession No. NM_001398), SRMS(GenBank Accession No. NM_080823), FRG1B(GenBank Accession No. NR_003579), SSTR4(GenBank Accession No. NM_001052), SLC12A5(GenBank Accession No. NM_020708), L3MBTL(GenBank Accession No. NM_032107), TCEA2(GenBank Accession No. NM_198723), FAM83C(GenBank Accession No. NM_178468), PHF20(GenBank Accession No. NM_016436), COX4I2(GenBank Accession No. NM_032609), CTCFL(GenBank Accession No. NM_080618), SALL4(GenBank Accession No. NM_020436), SLC13A3(GenBank Accession No. NM_022829), MYL9(GenBank Accession No. NM_006097), ADRA1D(GenBank Accession No. NM_000678), RTEL1(GenBank Accession No. NM_032957), BIRC7(GenBank Accession No. NM_139317), AIRE(GenBank Accession No. NM_000383), TFF1(GenBank Accession No. NM_003225), KRTAP10-6(GenBank Accession No. NM_198688), FTCD(GenBank Accession No. NM_006657), IGSF5(GenBank Accession No. NM_001080444), POTED(GenBank Accession No. NM_174981), PLAC4(GenBank Accession No. NM_182832), SNORA80(GenBank Accession No. NR_002996), MOV10L1(GenBank Accession No. NM_018995), HORMAD2(GenBank Accession No. NM_152510), LOC400931(GenBank Accession No. NR_027033), CACNA1I(GenBank Accession No. NM_021096), TMEM211(GenBank Accession No. NM_001001663), BAIAP2L2(GenBank Accession No. NM_025045), GSC2(GenBank Accession No. NM_005315), SUSD2(GenBank Accession No. NM_019601), GGT1(GenBank Accession No. NM_005265), RFPL2(GenBank Accession No. NM_001098527), MCHR1(GenBank Accession No. NM_005297), MAPK8IP2(GenBank Accession No. NM_012324), CHADL(GenBank Accession No. NM_138481), RGL4(GenBank Accession No. NM_153615), TCF20(GenBank Accession No. NM_005650), OTUD6A(GenBank Accession No. NM_207320), FAM9A(GenBank Accession No. NM_174951), RAB40AL(GenBank Accession No. NM_001031834), CT45A1(GenBank Accession No. NM_001017417), GJB1(GenBank Accession No. NM_000166), YY2(GenBank Accession No. NM_206923), FAM9B(GenBank Accession No. NM_205849)이 있다.GenBank Accession No. NM_019102), TPTE (GenBank Accession No. NM_199260), SPESP1 (GenBank Accession No. NM_145658), MIR200A (GenBank Accession No. NR_029834), NADK (GenBank Accession No. NR_026874), MOC663B (GenBank Accession No. NR_031608), ANKRD30BL (GenBank Accession No. NR_027020), UCN (GenBank Accession No. NM_003353), LOC100130872 (GenBank Accession No. NR_024569), SPON2 (GenBank Accession No. NM_001199021), MIR1229 (GenBank Accession No. NR_031598), C6orf201 (GenBank Accession No. NM_001085401), MEST (GenBank Accession No. NM_002402), SOHLH1 (GenBank Accession No. NM_001101677), SYCE1 (GenBank Accession No. (GenBank Accession No. NM_052997), KCNQ1DN (GenBank Accession No. NR_024627), AGAP2 (GenBank Accession No. NM_001122772), TDRD9 (GenBank Accession No. NM_153046), FAM181A (GenBank Accession No. NM_001207074), KLHL33 GenBank Accession No. NM_001109997), REREP3 (GenBank k Accession No. NR_033735), NOX5 (GenBank Accession No. Nos. GenBank Accession No. NR_038678), ALOX12 (GenBank Accession No. NM_000697), MIR3187 (GenBank Accession No. NR_036154), LOC100288123 (GenBank Accession No. NR_034114), EXOC3L2 (GenBank Accession No. NM_138568), MIR4745 GenBank Accession No. NR_039900), C19orf77 (GenBank Accession No. NM_001136503), C19orf34 (GenBank Accession No. NR_033400), MIR663 (GenBank Accession No. NR_030386), C20orf177 (GenBank Accession No. NM_001190826), GNAS (GenBank Accession No. NR_003259 ), TTLL10 (GenBank Accession No. NM_153254), FAM132A (GenBank Accession No. NM_001014980), C1orf146 (GenBank Accession No. NM_001012425), EIF2B3 (GenBank Accession No. NM_020365), CCDC27 (GenBank Accession No. NM_152492), CROCCL1 Accession No. NR_026752), FAM58B (GenBank Accession No. NM_001105517), TMEM61 (GenBank Accession No. NM_182532), OBSCN (GenBank Accession No. NM_052843), OBSCN (GenBank Accession No. NM_001098623), GPR25 (GenBank Accession No. NM_005298) , C1OrF 170 (GenBank Accession No. NR_027693), FGR (Ge nBank Accession No. (GenBank Accession No. NM_032129), GPR37L1 (GenBank Accession No. NM_032129), HSPA7 (GenBank Accession No. NR_024151), PER3 (GenBank Accession No. NM_016831), CLDN19 (GenBank Accession No. NM_001123395), MMEL1 GenBank Accession No. NM_004767), SLC25A44 (GenBank Accession No. NM_014655), ICMT (GenBank Accession No. NM_012405), KLF17 (GenBank Accession No. NM_173484), AFARP1 (GenBank Accession No. NR_002796), HIST3H3 ), OR2L13 (GenBank Accession No. NM_175911), PVRL4 (GenBank Accession No. NM_030916), EPS8L3 (GenBank Accession No. NM_139053), CLCNKA (GenBank Accession No. NM_004070), NCRNA00164 (GenBank Accession No. NR_027020), UCN Accession No. NM_003353), KRTCAP3 (GenBank Accession No. NM_173853), NCRNA00164 (GenBank Accession No. NR_027019), ANKMY1 (GenBank Accession No. NM_016552), TEKT4 (GenBank Accession No. NM_144705), LOC654433 (GenBank Accession No. NR_015377) , DNAJC5G (GenBank Accession No. NM_173650), C2orf54 (GenBank Accession No. NM_001 085437), ALPPL2 (GenBank Accession No. < / RTI > GenBank Accession No. NM_031313), KLHL30 (GenBank Accession No. NM_198582), POTEF (GenBank Accession No. NM_001099771), BOLL (GenBank Accession No. NM_033030), RGPD4 (GenBank Accession No. NM_182588), TUBA3D (GenBank Accession No. NM_080386), ARHGEF4 GenBank Accession No. NM_032995), RGPD3 (GenBank Accession No. NM_001144013), CRYGA (GenBank Accession No. NM_014617), PRLH (GenBank Accession No. NM_015893), LOC401010 (GenBank Accession No. NR_002826), MFSD2B (GenBank Accession No. NM_001080473 GenBank Accession No. NM_007046), SCTR (GenBank Accession No. NM_002980), C2orf39 (GenBank Accession No. NM_145038), NT5DC2 (GenBank Accession No. NM_022908), PRR23C (GenBank Accession No. NM_001134657), ITIH4 Accession No. NM_002218), DPPA2 (GenBank Accession No. NM_138815), RARRES1 (GenBank Accession No. NM_206963), GRK7 (GenBank Accession No. NM_139209), TM4SF19 (GenBank Accession No. NM_138461), OSTalpha (GenBank Accession No. NM_152672) , AMT (GenBank Accession No. NM_000481), PRSS50 (GenBank Accession No. NM_013270), HTR3E (GenBank Accession No. < / RTI > (GenBank Accession No. NM_014229), PRSS23 (GenBank Accession No. NM_014229), PRZ23A (GenBank Accession No. NM_001134659), SLC6A11 (GenBank Accession No. NM_014229) GenBank Accession No. NM_182702), LOC100130872 (GenBank Accession No. NR_024569), DCAF4L1 (GenBank Accession No. NM_001029955), C4orf44 (GenBank Accession No. NM_001042690), TRIM60 (GenBank Accession No. NM_152620), FAM92A3 ), ADAD1 (GenBank Accession No. NM_139243), RBM46 (GenBank Accession No. NM_144979), OTOP1 (GenBank Accession No. NM_177998), SLC26A1 (GenBank Accession No. NM_213613), RNF212 (GenBank Accession No. NM_001131034), LOC650293 Accession No. NM_001040071), ZNF595 (GenBank Accession No. NM_182524), FRG1 (GenBank Accession No. NM_004477), YTHDC1 (GenBank Accession No. NM_001031732), NAP1L5 (GenBank Accession No. NM_153757), COX7B2 (GenBank Accession No. NM_130902) , FTMT (GenBank Accession No. NM_177478), LRRC14B (GenBank Access ion No. GenBank Accession No. NM_031947), CMYA5 (GenBank Accession No. NM_153610), SLC6A19 (GenBank Accession No. NM_001003841), IL3 (GenBank Accession No. NM_000588), C5orf47 (GenBank Accession No. NM_001144954), DND1 GenBank Accession No. NM_194249), CDX1 (GenBank Accession No. NM_001804), SLC45A2 (GenBank Accession No. NM_016180), CDH9 (GenBank Accession No. NM_016279), FAM170A (GenBank Accession No. NM_182761), PDLIM4 ), PFN3 (GenBank Accession No. NM_001029886), ZDHHC11 (GenBank Accession No. NM_024786), LOC134466 (GenBank Accession No. NR_026867), PPP1R2P3 (GenBank Accession No. NR_002168), GMCL1L (GenBank Accession No. NR_003281), PLEKHG4B Accession No. NM_052909), IRX2 (GenBank Accession No. NM_033267), C6orf201 (GenBank Accession No. NM_001085401), HIST1H1A (GenBank Accession No. NM_005325), DUSP22 (GenBank Accession No. NM_020185), HDGFL1 (GenBank Accession No. NM_138574) , DDX43 (GenBank Accession No. NM_018665), PLAGL1 (GenBank Accession No. GenBank Accession No. NM_003547), DPBA5 (GenBank Accession No. NM_001025290), FAM50B (GenBank Accession No. NM_012135), FRMD1 (GenBank Accession No. NM_024919), PNLDC1 (GenBank Accession No. NM_173516), TDRD6 GenBank Accession No. NM_001010870), HUS1B (GenBank Accession No. NM_148959), ID4 (GenBank Accession No. NM_001546), MCART3P (GenBank Accession No. NR_026540), C6orf221 (GenBank Accession No. NM_001017361) , GenBank Accession No. NM_001080413, GenBank Accession No. NM_001080413), HOXA4 (GenBank Accession No. NM_002141), GPR146 (GenBank Accession No. NM_138445), ZNF716 (GenBank Accession No. NM_001159279), RAMP3 Accession No. NM_005856), AMZ1 (GenBank Accession No. NM_133463), SGCE (GenBank Accession No. NM_001099401), ELFN1 (GenBank Accession No. NM_001128636), CPA1 (GenBank Accession No. NM_001868), AMAC1L2 (GenBank Accession No. NM_054028) , TSPYL5 (GenBank Accession No. NM_033512), KIAA1875 (GenBank Accession No. NR_02 4207), DCAF4L2 (GenBank Accession No. GenBank Accession No. NM_017767), HTRA4 (GenBank Accession No. NM_153692), POTEA (GenBank Accession No. NM_001005365), PTP4A3 (GenBank Accession No. NM_032611), CSMD3 (GenBank Accession No. NM_198124), NRBP2 (GenBank Accession No. NM_0079564), GPT (GenBank Accession No. NM_0053064), GenBank Accession No. NM_0059564), LOC100130274 , GenBank Accession No. NM_022133), SOHLH1 (GenBank Accession No. NM_001080431), MAPK15 (GenBank Accession No. NM_139021), LRRC24 (GenBank Accession No. NM_001024678), RP1L1 (GenBank Accession No. NM_178857), SLC45A4 Accession No. NM_001012415), EGFL7 (GenBank Accession No. NM_016215), PTGDS (GenBank Accession No. NM_000954), NPR2 (GenBank Accession No. NM_003995), DBH (GenBank Accession No. NM_000787), NR5A1 (GenBank Accession No. NM_004959) , FAM166A (GenBank Accession No. NM_001001710), C9orf135 (GenBank Accession No. N M_001010940), MAMDC4 (GenBank Accession No. (GenBank Accession No. NM_052813), OR13J1 (GenBank Accession No. NM_001004487), C9orf152 (GenBank Accession No. NM_001012993), POMT1 (GenBank Accession No. NM_001136113), TMC1 (GenBank Accession No. NM_13691), CACNA1B GenBank Accession No. NM_000718), PRKACG (GenBank Accession No. NM_002732), PAEP (GenBank Accession No. NM_001018049), S1PR3 (GenBank Accession No. NM_005226), SNORD62A (GenBank Accession No. NR_002914), ANKRD30A (GenBank Accession No. NM_052997 ), C10orf116 (GenBank Accession No. NM_006829), GPR26 (GenBank Accession No. NM_153442), CTBP2 (GenBank Accession No. NM_022802), CCNY (GenBank Accession No. NM_181698), PNLIPRP2 (GenBank Accession No. NM_005396), PYROXD2 Accession No. NM_032709), GDF2 (GenBank Accession No. NM_016204), MMP21 (GenBank Accession No. NM_147191), CALML3 (GenBank Accession No. NM_005185), JAKMIP3 (GenBank Accession No. NM_001105521), ANKRD2 (GenBank Accession No. NM_020349) , C10orf108 (GenBank Accession No. NR_027152), IDI2 (GenBank Accession No. NM_033261), RBP3 (GenBank Accession No. 2). TUBB8 (GenBank Accession No. NM_174987), TUBGCP2 (GenBank Accession No. NM_006659), KCNQ1DN (GenBank Accession No. NR_024627), LOC441601 (GenBank Accession No. NR_003034), SPDYC (GenBank Accession No. NM_001008778), CD248 GenBank Accession No. NM_020404), TSSC4 (GenBank Accession No. NM_005706), H19 (GenBank Accession No. NR_002196), LDHAL6A (GenBank Accession No. NM_144972), FOXR1 (GenBank Accession No. NM_181721), PKP3 ), MS4A15 (GenBank Accession No. NM_001098835), MRGPRE (GenBank Accession No. NM_001039165), MUC6 (GenBank Accession No. NM_005961), LSP1 (GenBank Accession No. NM_002339), TNNT3 (GenBank Accession No. NM_006757), TP53AIP1 Accession No. NM_022112), CATSPER1 (GenBank Accession No. NM_053054), TAGLN (GenBank Accession No. NM_001001522), CABP2 (GenBank Accession No. NM_016366), GNG3 (GenBank Accession No. NM_012202) , FOLR3 (GenBank Accession No. NM_000804), TMEM218 (GenBank Accession No. NM_001080546), TBX10 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_005995), SCGB2A1 (GenBank Accession No. NM_002407), C11orf36 (GenBank Accession No. NR_027138), DRD4 (GenBank Accession No. NM_000797), MUC2 (GenBank Accession No. NM_002457), AGAP2 (GenBank Accession No. NM_001122772), RPL13AP20 GenBank Accession No. NM_003932), FIGNL2 (GenBank Accession No. NM_001013690), ACRBP (GenBank Accession No. NM_032489), SLC6A12 (GenBank Accession No. NM_003044), KRT3 (GenBank Accession No. NM_057088), TUBGCP3 ), SOHLH2 (GenBank Accession No. NM_017826), ATP4B (GenBank Accession No. NM_000705), RNF17 (GenBank Accession No. NM_031277), TUBA3C (GenBank Accession No. NM_006001), CSNK1A1L (GenBank Accession No. NM_145203), DLEU7 Accession No. NM_198989), TDRD9 (GenBank Accession No. NM_153046), DIO3 (GenBank Accession No. NM_001362), COX8C (GenBank Accession No. NM_182971), ASPG (GenBank Accession No. NM_001080464), MGC23270 (GenBank Accession No. NR_024396) , RPL13AP3 (GenBank Accession No. NR_004844), RPS6KL1 (GenBank Accession No. NM_031464 ), ACOT4 (GenBank Accession No. 2). GenBank Accession No. NM_99447), GenBank Accession No. NM_022489), AMN (GenBank Accession No. NM_030943), ABHD12B (GenBank Accession No. NM_181533), TBPL2 (GenBank Accession No. NM_199047), PSMB11 GenBank Accession No. NM_001099780), CATSPER2 (GenBank Accession No. NM_054020), LOC390594 (GenBank Accession No. NM_001101362), C15orf2 (GenBank Accession No. NM_018958), PCSK6 (GenBank Accession No. NM_002570), C15orf60 (GenBank Accession No. NM_001042367 ), SNORD115-6 (GenBank Accession No. NR_003298), SNORD115-17 (GenBank Accession No. NR_003309), RASL12 (GenBank Accession No. NM_016563), SNORD115-32 (GenBank Accession No. NR_003347), SNORD115-31 (GenBank Accession No. NM_003346), LASS3 (GenBank Accession No. NM_178842), SNORD115-37 (GenBank Accession No. NR_003352), LDHAL6B (GenBank Accession No. NM_033195), GABRB3 (GenBank Accession No. NM_000814), SNORD115-25 , SLC28A2 (GenBank Accession No. NM_004212), ZNF469 (GenBank Accession No. NM_001127464), CC DC154 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_027242), CLDN9 (GenBank Accession No. NM_001143980), TESSP1 (GenBank Accession No. NM_001135086), ELMO3 (GenBank Accession No. NM_024712), ZSCAN10 (GenBank Accession No. NM_032805), PDIA2 (GenBank Accession No. NM_006849), LOC146336 GenBank Accession No. NM_020982), CLDN6 (GenBank Accession No. NM_021195), IGFALS (GenBank Accession No. NM_001146006), IL34 (GenBank Accession No. NM_152456), NAT15 (GenBank Accession No. NM_001083601), SSTR5 (GenBank Accession No. NM_001053 ), DNASE1L2 (GenBank Accession No. NM_001374), MSLN (GenBank Accession No. NM_005823), CMTM1 (GenBank Accession No. NM_052999), FBRS (GenBank Accession No. NM_001105079), ZNF597 (GenBank Accession No. NM_152457), SLC5A11 Accession No. NM_052944), IL17C (GenBank Accession No. NM_013278), FAM18A (GenBank Accession No. NM_001079512), TPSG1 (GenBank Accession No. NM_012467), GPR97 (GenBank Accession No. NM_170776), PRM2 (GenBank Accession No. NM_002762) , JMJD8 (GenBank Accession No. NM_001005920), ADAD2 (GenBank Accession No. NM_13917 4), C16orf81 (GenBank Accession No. 4). (GenBank Accession No. NM_012347), TPSD1 (GenBank Accession No. NM_012217), ADCY7 (GenBank Accession No. NM_001114), ZG16B (GenBank Accession No. NM_145252), CHST5 (GenBank Accession No. NM_024533), PRR25 GenBank Accession No. NM_001089), CCDC79 (GenBank Accession No. NM_001136505), WDR59 (GenBank Accession No. NM_030581), GLIS2 (GenBank Accession No. NM_032575), MT1L (GenBank Accession No. NR_001447), TMPRSS8 (GenBank Accession No. NR_026864 ), TMC7 (GenBank Accession No. NM_024847), DNASE1 (GenBank Accession No. NM_005223), ALOX12 (GenBank Accession No. NM_000697), KCNAB3 (GenBank Accession No. NM_004732), DYSFIP1 (GenBank Accession No. NM_001007533), QRICH2 Accession No. NM_032134), FSCN2 (GenBank Accession No. NM_012418), CACNG1 (GenBank Accession No. NM_000727), TMEM88 (GenBank Accession No. NM_203411), UTS2R (GenBank Accession No. NM_018949), HSPB9 (GenBank Accession No. NM_033194) , NLGN2 (GenBank Accession No. NM_020795), FOXO3B (GenBank Accession No. NR_026718), FLJ36000 ( GenBank Accession No. GenBank Accession No. NM_006987), GGT6 (GenBank Accession No. NM_001122890), RAB34 (GenBank Accession No. NM_031934), SHISA6 (GenBank Accession No. NM_207386), GPR172B (GenBank Accession No. NM_001104577), SLFN13 GenBank Accession No. NM_144682), HSF5 (GenBank Accession No. NM_001080439), ENPP7 (GenBank Accession No. NM_178543), AIPL1 (GenBank Accession No. NM_014336), AMAC1 (GenBank Accession No. NM_152462), KCTD11 (GenBank Accession No. NM_001002914 GenBank Accession No. NM_015626), SERPINF1 (GenBank Accession No. NM_002615), ULK2 (GenBank Accession No. NM_014683), TBX4 (GenBank Accession No. NM_018488), CCDC144NL (GenBank Accession No. NM_001004306), KCNG2 Accession No. NM_012283), RNF138 (GenBank Accession No. NM_016271), ANKRD30B (GenBank Accession No. NM_001145029), PSMA8 (GenBank Accession No. NM_144662), CNDP1 (GenBank Accession No. NM_032649), EXOC3L2 (GenBank Accession No. NM_138568) , C19orf77 (GenBank Accession No. NM_001136503), C19orf34 (GenBank Accession No. GenBank Accession No. NM_031310), FJR1 (GenBank Accession No. NM_001136198), TMPRSS9 (GenBank Accession No. NM_182973), ZNF558 (GenBank Accession No. NM_144693), PLVAP (GenBank Accession No. NM_031310), YJEFN3 (GenBank Accession No. NM_198537), CCDC155 GenBank Accession No. NM_144688), TMEM86B (GenBank Accession No. NM_173804), SPACA4 (GenBank Accession No. NM_133498), PRR22 (GenBank Accession No. NM_001134316), ELANE (GenBank Accession No. NM_001972), ACPT (GenBank Accession No. NM_033068 ), PSPN (GenBank Accession No. NM_004158), WDR88 (GenBank Accession No. NM_173479), PLIN4 (GenBank Accession No. NM_001080400), OR10H1 (GenBank Accession No. NM_013940), CCDC105 (GenBank Accession No. NM_173482), SNORD37 Accession No. NR_002602), DUS3L (GenBank Accession No. NM_020175), CBLC (GenBank Accession No. NM_012116), LGALS4 (GenBank Accession No. NM_006149), COX7A1 (GenBank Accession No. NM_001864), KCNA7 (GenBank Accession No. NM_031886) , NTN5 (GenBank Accession No. NM_145807), SNORD35A (GenBank Accession No. NR_000018), FFAR2 (GenBank Accession No. 2). GenBank Accession No. NM_18572), LOC126536 (GenBank Accession No. NR_026828), LYPD4 (GenBank Accession No. NM_173506), DMRTC2 (GenBank Accession No. NM_001040283), ACTL9 (GenBank Accession No. NM_178525), TDRD12 GenBank Accession No. NM_001110822), CAPS (GenBank Accession No. NM_004058), PGLYRP1 (GenBank Accession No. NM_005091), CAPN12 (GenBank Accession No. NM_144691), FAM83E (GenBank Accession No. NM_017708), NLRP4 (GenBank Accession No. NM_134444 , GenBank Accession No. NM_003712), UPK1A (GenBank Accession No. NM_007000), INSL3 (GenBank Accession No. NM_005543), KCNJ14 (GenBank Accession No. NM_170720), ODF3L2 (GenBank Accession No. NM_182577), PLK5P Accession No. NR_026557), AURKC (GenBank Accession No. NM_001015878), ECH1 (GenBank Accession No. NM_001398), SRMS (GenBank Accession No. NM_080823), FRG1B (GenBank Accession No. NR_003579), SSTR4 (GenBank Accession No. NM_001052) , SLC12A5 (GenBank Accession No. NM_020708), L3MBTL (GenBank Accession No. NM_032107), TCEA2 (GenBank Accession No. 2). (GenBank Accession No. NM_020436), SLC13A3 (GenBank Accession No. NM_020436), and SLC13A3 (GenBank Accession No. NM_020436), FAM83C (GenBank Accession No. NM_178468), PHF20 (GenBank Accession No. NM_016436), COX4I2 (GenBank Accession No. NM_032609), CTCFL GenBank Accession No. NM_022829), MYL9 (GenBank Accession No. NM_006097), ADRA1D (GenBank Accession No. NM_000678), RTEL1 (GenBank Accession No. NM_032957), BIRC7 (GenBank Accession No. NM_139317) ), TFF1 (GenBank Accession No. NM_003225), KRTAP10-6 (GenBank Accession No. NM_198688), FTCD (GenBank Accession No. NM_006657), IGSF5 (GenBank Accession No. NM_001080444), POTED (GenBank Accession No. NM_174981) (GenBank Accession No. NM_182832), SNORA80 (GenBank Accession No. NR_002996), MOV10L1 (GenBank Accession No. NM_018995), HORMAD2 (GenBank Accession No. NM_152510), LOC400931 (GenBank Accession No. NR_027033), CACNA1I (GenBank Accession No. NM_021096), TMEM211 (GenBank Accession No. NM_001001663), BAIAP2L2 (GenBank Accession No. NM_025045), GSC2 (GenBank Accession No. < / RTI > GenBank Accession No. NM_012324), CHADL (GenBank Accession No. NM_012324), SUSD2 (GenBank Accession No. NM_019601), GGT1 (GenBank Accession No. NM_005265), RFPL2 (GenBank Accession No. NM_001098527), MCHR1 GenBank Accession No. NM_138481), RGL4 (GenBank Accession No. NM_153615), TCF20 (GenBank Accession No. NM_005650), OTUD6A (GenBank Accession No. NM_207320), FAM9A (GenBank Accession No. NM_174951), RAB40AL (GenBank Accession No. NM_001031834 ), CT45A1 (GenBank Accession No. NM_001017417), GJB1 (GenBank Accession No. NM_000166), YY2 (GenBank Accession No. NM_206923), and FAM9B (GenBank Accession No. NM_205849).
상기 기재된 유전자들은 정상인 대조군에 비하여 2배 내지 4배 정도 메틸화 수준이 높은 특징이 있다(실시예 2-3 참조). 상기 유전자의 이러한 특징은 본 발명에서 최초로 공개되는 것이다.
The genes described above are characterized by a
뿐만 아니라, 본 발명은 TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 및 PPAPDC3(GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 조성물을 제공한다.In addition, the present invention measures the expression level or methylation level of any one gene selected from the group consisting of TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) and PPAPDC3 (GenBank Accession No. NM_032728) A composition for the diagnosis of psoriasis.
본 발명에서 용어, "유전자의 발현수준을 측정하는 제제"란 상기와 같이 건선 세포에서 발현이 증가하는 마커인 상기 유전자의 mRNA 또는 단백질의 발현 수준을 확인함으로써 마커의 검출에 사용될 수 있는 분자를 의미하며, 바람직하게는 상기 유전자와 특이적으로 결합하는 프라이머. 프로브 또는 상기 유전자의 발현 단백질으로 특이적으로 인식하는 항체를 말한다. 더 바람직하게는 상기 유전자의 mRNA를 증폭할 수 있는 프라이머일 수 있다. 가장 바람직하게 상기 프라이머는 서열번호 1 및 2의 프라이머쌍, 서열번호 3 및 4의 프라이머쌍 및 서열번호 5 및 6의 프라이머쌍으로 이루어진 군에서 선택되는 어느 하나 이상의 프라이머 쌍일 수 있다. The term "agent for measuring the expression level of a gene" in the present invention means a molecule that can be used for detecting a marker by confirming the expression level of the mRNA or protein of the gene, which is a marker for increasing expression in psoriatic cells, And is preferably a primer that specifically binds to the gene. Refers to an antibody specifically recognized as a probe or an expression protein of the gene. More preferably, it may be a primer capable of amplifying mRNA of the gene. Most preferably, the primer may be any one or more primer pairs selected from the group consisting of the primer pairs of SEQ ID NOs: 1 and 2, the primer pairs of SEQ ID NOs: 3 and 4, and the primer pairs of SEQ ID NOs: 5 and 6.
본 명세서에서 용어 "프라이머"는 적합한 온도에서 적합한 완충액 내에서 적합한 조건(즉, 4종의 다른 뉴클레오사이드 트리포스페이트 및 중합반응 효소)하에서 주형-지시 DNA 합성의 개시점으로 작용할 수 있는 단일-가닥 올리고뉴클레오타이드를 의미한다. 프라이머의 적합한 길이는 다양한 인자, 예컨대, 온도와 프라이머의 용도에 따라 변이가 있지만 전형적으로 15-30 뉴클레오타이드이다. 짧은 프라이머 분자는 주형과 충분히 안정된 하이브리드 복합체를 형성하기 위하여 일반적으로 보다 낮은 온도를 요구한다.As used herein, the term "primer" refers to a single-stranded DNA strand that can act as a starting point for template-directed DNA synthesis under suitable conditions (i. E., Four other nucleoside triphosphates and polymerase) Means an oligonucleotide. The suitable length of the primer is typically 15-30 nucleotides, although it varies depending on various factors such as temperature and use of the primer. Short primer molecules generally require lower temperatures to form sufficiently stable hybrid complexes with the template.
프라이머의 서열은 주형의 일부 서열과 완전하게 상보적인 서열을 가질 필요는 없으며, 주형과 혼성화되어 프라이머 고유의 작용을 할 수 있는 범위 내에서의 충분한 상보성을 가지면 충분하다. 따라서 본 발명에서의 프라이머쌍은 주형인 표적 유전자 서열에 완벽하게 상보적인 서열을 가질 필요는 없으며, 이 서열에 혼성화되어 프라이머 작용을 할 수 있는 범위 내에서 충분한 상보성을 가지면 충분하다. 본 발명의 프라이머는 표적 유전자의 mRNA (즉, cDNA) 서열에 상보적인 서열로 제조될 수 있다. 이러한 프라이머의 디자인은 표적 유전자의 cDNA 서열을 참조하여 당업자에 의해 용이하게 실시할 수 있다.The sequence of the primer does not need to have a sequence completely complementary to a partial sequence of the template, and it is sufficient if the primer has sufficient complementarity within a range capable of hybridizing with the template and acting as a primer. Therefore, the primer pair in the present invention does not need to have a perfectly complementary sequence to the target gene sequence as a template, and it is sufficient that the primer pair has sufficient complementarity within a range capable of hybridizing to the sequence and acting as a primer. The primer of the present invention can be prepared with a sequence complementary to the mRNA (i.e., cDNA) sequence of the target gene. The design of such a primer can be easily carried out by those skilled in the art with reference to the cDNA sequence of the target gene.
용어 "프로브"란 mRNA외 특이적으로 결합을 이룰 수 있는 짧게는 수 염기 내지 길게는 수백 염기에 해당하는 RNA 또는 DNA 등의 핵산 단편을 의미하며 라벨링되어 있어서 특정 mRNA의 존재 유무, 발현양을 확인할 수 있다.The term "probe" means a nucleic acid fragment such as RNA or DNA corresponding to a few nucleotides or several hundreds of nucleotides that can specifically bind to an mRNA, and is labeled to confirm the presence or expression level of a specific mRNA .
프로브는 올리고뉴클레오타이드(oligonucleotide) 프로브, 단쇄 DNA(single strand DNA) 프로브, 이중쇄 DNA(double strand DNA)프로브, RNA 프로브 등의 형태로 제작될 수 있다. TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 또는 PPAPDC3(GenBank Accession No. NM_032728) 폴리뉴클레오티드의 mRNA와 상보적인 프로브를 이용하여 혼성화를 실시하여, 혼성화 정도를 통해 mRNA의 발현양을 측정함으로써 방사선 피폭 여부 및 정도를 측정할 수 있다. 적절한 프로브의 선택 및 혼성화 조건은 당해 기술분야에 공지된 기술에 따라 적절히 선택할 수 있다.The probe may be prepared in the form of an oligonucleotide probe, a single strand DNA probe, a double strand DNA probe, or an RNA probe. Hybridization was performed using a probe complementary to mRNA of TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) or PPAPDC3 (GenBank Accession No. NM_032728) polynucleotide, and the expression amount of mRNA And the degree of radiation exposure can be measured. Selection of suitable probes and hybridization conditions can be appropriately selected according to techniques known in the art.
본 발명의 프라이머 또는 프로브는 포스포아미다이트(phosphoramidite) 고체 지지체 합성법이나 기타 널리 공지된 방법을 이용하여 화학적으로 합성할 수 있다. 이러한 핵산 서열은 또한 당해 기술분야에 공지된 다양한 방법을 통해 변형시킬 수 있다. 이러한 변형의 예로는 메틸화, 캡화, 천연 뉴클레오티드 하나 이상의 동족체로의 치환, 및 뉴클레오티드 간의 변형, 예를 들면 하전되지 않은 연결체(예: 메틸 포스포네이트, 포스포트리에스테르, 포스포로아미데이트, 카바메이트 등) 또는 하전된 연결체(예: 포스포로티오에이트, 포스포로디티오에이트 등)로의 변형이 있다.The primer or probe of the present invention can be chemically synthesized using a phosphoramidite solid support synthesis method or other well-known methods. Such nucleic acid sequences may also be modified through a variety of methods known in the art. Examples of such modifications include, but are not limited to, methylation, capping, substitution with one or more of the natural nucleotide analogs, and modifications between nucleotides, such as uncharged linkers (e.g., methylphosphonate, phosphotriester, phosphoramidate, carbamate Etc.) or charged conjugates (e.g., phosphorothioates, phosphorodithioates, etc.).
용어 "항체"란 당해 기술분야에 공지된 용어로서 항원성 부위에 대하여 지시되는 특이적인 면역 글로불린을 의미한다. 본 발명에서의 항체는 본 발명의 건선 마커인 TP73, FANK1 또는 PPAPDC3에 대해 특이적으로 결합하는 항체를 의미하며, TP73, FANK1 또는 PPAPDC3 유전자를 발현벡터에 클로닝하여 상기 유전자에 의해 코딩되는 단백질을 얻고, 얻어진 단백질로부터 당해 기술분야의 통상적인 방법에 따라 항체를 제조할 수 있다. 상기 항체의 형태는 폴리클로날 항체 또는 모노클로날 항체를 포함하며, 모든 면역글로불린 항체가 포함된다. 상기 항체는 2개의 전체 길이의 경쇄 및 2 개의 전체 길이의 중쇄를 갖는 완전한 형태를 의미한다. 또한, 상기 항체는 인간화 항체 등의 특수 항체도 포함된다.The term "antibody ", as the term is known in the art, refers to a specific immunoglobulin directed against an antigenic site. The antibody in the present invention refers to an antibody specifically binding to TP73, FANK1 or PPAPDC3 of the present invention. The TP73, FANK1 or PPAPDC3 gene is cloned into an expression vector to obtain a protein encoded by the gene , And the antibody can be prepared from the obtained protein according to a conventional method in the art. The forms of the antibodies include polyclonal or monoclonal antibodies, including all immunoglobulin antibodies. The antibody refers to a complete form having two full-length light chains and two full-length heavy chains. The antibody also includes a special antibody such as a humanized antibody.
본 발명에서 "유전자의 메틸화 수준을 측정하는 제제"는 건선이 의심되는 환자의 TP73, FANK1 또는 PPAPDC3 유전자의 메틸화된 대립형질 서열에 특이적인 프라이머 및 비메틸화된 대립형질 서열에 특이적인 프라이머를 포함할 수 있다. 또한, 본 발명의 제제는 건선이 의심되는 환자의 TP73, FANK1 또는 PPAPDC3 유전자의 변형된 유전자의 대립형질 서열에 특이적인 프라이머 쌍 및 확장 프라이머를 포함할 수 있다.In the present invention, the phrase "agent for measuring the level of methylation of a gene" includes a primer specific to the methylated allele sequence of the TP73, FANK1 or PPAPDC3 gene of a patient suspected of having psoriasis and a primer specific to the unmethylated allele sequence . In addition, the agent of the present invention may include a primer pair and an extension primer that are specific for the allelic sequence of the modified gene of the TP73, FANK1, or PPAPDC3 gene in psoriasis-susceptible patients.
상기 프라이머는 메틸화 여부를 분석하는 대상이 되는 CpG 섬의 서열에 따라 바람직하게 디자인될 수 있으며, 각각 메틸화되어 바이설파이트에 의해 변형되지 않았던 사이토신을 특이적으로 증폭할 수 있는 프라이머 쌍 및 메틸화되지 않아 바이설파이트에 의해 변형된 사이토신을 특이적으로 증폭할 수 있는 프라이머쌍일 수 있다. 또한, 변형된 서열에 특이적인 프라이머 쌍 및 확장 프라이머일 수 있다.The primers can be designed according to the sequence of the CpG islands to be subjected to methylation analysis, and each primer pair can be specifically designed to amplify cytosine that is methylated and not modified by bisulfite, It may be a pair of primers capable of specifically amplifying cytosine modified by bisulfite. It may also be a primer pair and extension primer specific for the modified sequence.
또한, 본 발명에서 유전자의 메틸화 수준을 측정하는 제제는 비메틸화된 사이토신 염기를 변형시키는 화합물, 상기 유전자의 변형된 서열에 특이적인 프라이머 쌍 및 확장 프라이머 (extension primer)를 포함할 수 있다.Also, in the present invention, the agent for measuring the methylation level of a gene may include a compound that modifies an unmethylated cytosine base, a primer pair specific to a modified sequence of the gene, and an extension primer.
상기 비메틸화된 사이토신 염기를 변형시키는 화합물은 바이설파이트 (bisulfite)일 수 있으나 이에 제한되지 않으며, 바람직하게는 소듐 바이설파이트이다. 이러한 바이설파이트를 이용하여 비메틸화된 사이토신 잔기를 변형시켜 프로모터의 메틸화 여부를 검출하는 방법은 당업계에 널리 공지되어 있다(Herman JG et al., 1996, Proc. Natl. Acad. Sci. USA, 93: 9821 - 9826; WO01/26536; US2003/0148326A1).The compound that transforms the unmethylated cytosine base may be bisulfite, but is not limited thereto, preferably sodium bisulfite. Methods for detecting the methylation of a promoter by modifying an unmethylated cytosine residue using such a bisulfite are well known in the art (Herman JG et al., 1996, Proc. Natl. Acad. Sci. USA , 93: 9821-9826; WO01 / 26536; US2003 / 0148326A1).
또한, 상기 메틸화 민감성 제한효소는 CpG 섬의 메틸화를 특이적으로 검출할 수 있는 제한효소로서, 바람직하게는 제한효소의 인식부위로 CG를 함유하는 제한효소이다. 예를 들면, SmaI, SacII, EagI, HpaII, MspI, BssHII, BstUI, NotI 등이 있으며 이에 제한되지 않는다. 상기 제한효소 인식부위의 C에서의 메틸화 또는 비메틸화에 따라 제한효소에 의한 절단 여부가 달라지고 이를 PCR 또는 서던블롯 (Southern Blot) 분석을 통해 검출할 수 있게 된다. 상기 제한효소 이외의 다른 메틸화 민감성 제한효소는 당업계에 잘 알려져 있다.In addition, the methylation-sensitive restriction enzyme is a restriction enzyme capable of specifically detecting the methylation of CpG island, and is preferably a restriction enzyme containing CG as a recognition site of a restriction enzyme. For example, SmaI, SacII, EagI, HpaII, MspI, BssHII, BstUI, NotI, and the like. The methylation or non-methylation of the restriction enzyme recognition site at C may or may not be cleaved by restriction enzymes and may be detected by PCR or Southern blot analysis. Other methylation sensitive restriction enzymes than the above restriction enzymes are well known in the art.
본 발명의 건선 진단용 조성물에는 상기 제제 이외에도, 중합효소, 아가로스, 전기영동에 필요한 완충용액 등이 추가로 포함될 수 있다.
The composition for diagnosing psoriasis according to the present invention may further contain a polymerase, agarose, buffer solution necessary for electrophoresis, etc., in addition to the above-mentioned preparation.
또한 본 발명은 TP73(서열번호 9 / GenBank Accession No. NM_001126240), FANK1 (서열번호 10 / GenBank Accession No. NM_145235) 및 PPAPDC3(서열번호 11 / GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 측정하는 제제를 포함하는 건선 진단용 키트를 제공한다. The present invention also relates to a pharmaceutical composition comprising a compound selected from the group consisting of TP73 (SEQ ID NO: 9 / GenBank Accession No. NM_001126240), FANK1 (SEQ ID NO: 10 / GenBank Accession No. NM_145235) and PPAPDC3 (SEQ ID NO: 11 / GenBank Accession No. NM_032728) Or a methylation level of the gene of the present invention.
상기 "유전자의 발현수준 또는 메틸화 수준을 측정하는 제제"는 상기 건선 진단용 조성물에 기재한 바와 같다.The "agent for measuring the expression level or methylation level of the gene" is as described for the composition for diagnosing psoriasis.
바람직하게, 상기 건선 진단 키트는 분석 방법에 적합한 한 종류 또는 그 이상의 다른 구성성분 조성물, 용액 또는 장치를 더 포함하여 구성될 수 있다. 구체적인 일 양태로서, 상기 진단 키트는 역전사 중합효소반응을 수행하기 위해 필요한 필수 요소를 포함하는 것을 특징으로 하는 진단용 키트일 수 있다. 역전사 중합효소반응 키트는 마커 유전자에 대한 특이적인 각각의 프라이머를 포함한다. 상기 프라이머는 바람직하게는 서열번호 1 및 2의 프라이머쌍, 서열번호 3 및 4의 프라이머쌍 및 서열번호 5 및 6의 프라이머쌍으로 이루어진 군에서 선택되는 어느 하나 이상의 프라이머 쌍일 수 있다. 또한 대조군 유전자의 핵산 서열에 특이적인 프라이머를 포함할 수 있다. 그 외 역전사 중합효소반응 키트는 테스트 튜브 또는 다른 적절한 컨테이너, 반응 완충액(pH 및 마그네슘 농도는 다양), 데옥시뉴클레오타이드(dNTPs), Taq-폴리머라아제 및 역전사효소와 같은 효소, DNAse, RNAse 억제제 DEPC-수(DEPC-water), 멸균수 등을 포함할 수 있다.Preferably, the psoriasis diagnostic kit may further comprise one or more other component compositions, solutions or devices suitable for the assay method. In a specific embodiment, the diagnostic kit may be a diagnostic kit comprising essential elements necessary for performing a reverse transcription-polymerase reaction. The RT-PCR kit contains the respective primers specific for the marker gene. The primer may preferably be any one or more primer pairs selected from the group consisting of the primer pairs of SEQ ID NOs: 1 and 2, the primer pairs of SEQ ID NOs: 3 and 4, and the primer pairs of SEQ ID NOs: 5 and 6. It may also contain a primer specific for the nucleic acid sequence of the control gene. Other reverse transcription polymerase reaction kits may be used in combination with test tubes or other appropriate containers, reaction buffers (varying in pH and magnesium concentration), deoxynucleotides (dNTPs), enzymes such as Taq polymerase and reverse transcriptase, DNAse, RNAse inhibitor DEPC DEPC-water, sterile water, and the like.
또 다른 양태로는, 바람직하게 DNA 칩을 수행하기 위해 필요한 필수 요소를 포함하는 것을 특징으로 하는 진단 키트일 수 있다. DNA 칩 키트는 유전자 또는 그의 단편에 해당하는 cDNA 또는 올리고뉴클레오티드(oligonucleotide)가 부착되어 있는 기판, 및 형광표식 프로브를 제작하기 위한 시약, 제제, 효소 등을 포함할 수 있다. 또한 기판은 대조군 유전자 또는 그의 단편에 해당하는 cDNA 또는 올리고뉴클레오티드를 포함할 수 있다.
In another embodiment, it may be a diagnostic kit, preferably comprising an essential element necessary for carrying out a DNA chip. The DNA chip kit may include a substrate to which a cDNA or oligonucleotide corresponding to a gene or a fragment thereof is attached, and reagents, preparations, enzymes, and the like for producing a fluorescent-labeled probe. The substrate may also comprise a cDNA or oligonucleotide corresponding to a control gene or fragment thereof.
본 발명의 TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 및 PPAPDC3(GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자의 발현수준 또는 메틸화 수준을 이용한 건선 진단에 필요한 정보를 제공하는 방법, 건선 진단용 조성물 및 진단용 키트를 제공한다. 본 발명은 건선 질환의 진단에 효과적이다.
In the diagnosis of psoriasis using the expression level or methylation level of any one gene selected from the group consisting of TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) and PPAPDC3 (GenBank Accession No. NM_032728) A method for providing necessary information, a composition for diagnosing psoriasis, and a diagnostic kit. The present invention is effective for diagnosing psoriasis.
도 1은 10kb 단위로 분석된 건선 환자, 아토피 환자의 Genome-wide dMES 값을 비교한 그래프이다. (Y축 : 건선환자의 dMES, X축 : 아토피 환자의 dMES)
도 2는 건선환자와 아토피 환자의 유전자 단위 MES 값을 비교한 그래프이다.
(각 그래프에서 Y축: 정상인군의 MES 값, X 축 : 건선환자 또는 아토피 환자의 MES 값)
도 3의 A는 각 유전자 별 mRNA 발현 수준을 비교한 그래프이다.(Normal : 정상인 대조군, Pso patient : 건선 환자군)
도 3의 B는 5-azacytidine(메틸화 저해제) 처리로 인한 mRNA 발현 수준을 측정한 그래프이다. ( 24-, 48- : 24시간 또는 48시간 5-azacytidine 비처리한 건선 환자군, 24 +5aza, 48 +5aza : 24시간 또는 48시간 5-azacytidine 처리한 건선 환자군)
도 4의 A는 TP73 유전자의 promoter 부위의 기능분석과, 연속 결손분석을 통한 특정 부위의 기능을 luciferase activity assay를 이용하여 분석한 그래프이다.
도 4의 B는 TP73 유전자의 promoter 부위의 메틸화에 따른 활성 차이를 in vitro methylation과 luciferease activity assay를 이용하여 분석한 그래프이다. FIG. 1 is a graph comparing genome-wide dMES values of psoriasis patients and atopic patients analyzed by 10 kb. (Y axis: dMES of psoriasis patients, X axis: dMES of atopic patients)
FIG. 2 is a graph comparing the gene unit MES values of psoriasis patients and atopic patients.
(Y axis in each graph: MES value of normal group, X axis: MES value of psoriasis patient or atopic patient)
3 (A) is a graph comparing mRNA expression levels of each gene (Normal: normal control group, Pso patient: psoriasis group)
FIG. 3B is a graph showing mRNA expression levels measured by 5-azacytidine (methylation inhibitor) treatment. (24-, 48-: 24 or 48 hours 5-azacytidine untreated psoriasis patients, 24 + 5aza, 48 + 5aza: 24 or 48 hours 5-azacytidine treated psoriasis patients)
FIG. 4A is a graph showing the functional analysis of the promoter region of the TP73 gene and the analysis of the function of a specific site through continuous defect analysis using the luciferase activity assay.
FIG. 4B is a graph showing the activity of methylation of the promoter region of the TP73 gene, using in vitro methylation and luciferase activity assay.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<실시예 1> ≪ Example 1 >
말초 혈액의 total CD4Total CD4 of peripheral blood
++
T cell의 DNA 확보 Securing T cell DNA
<1-1> 연구 대상자 선정<1-1> Selection of study subjects
임상의의 기준에 따라 가족력이 있으며, 지난 2년간 치료를 받지 않은 15세 이상의 성인 중에서 판상 건선(plaque type)의 건선 및 아토피 남자 환자 각각 15명과 12명, 그리고 정상 대조군 남자 11명으로부터 가톨릭의과대학 생명윤리심의위원회의 승인을 받아 연구에 대한 설명문을 충분히 이해하고 동의한 자발적 참여자를 대상으로 선정하였다.
Patients aged 15 years or older who have not been treated for the past 2 years have 15 or 12 plaques of psoriasis and 12 atopic men and 11 normal control men. And volunteer participants who fully understand and agree with the explanatory text of the study with the approval of the Bioethics Review Committee.
<1-2> Total CD4<1-2> Total CD4 ++ T cell 분리 T cell separation
상기 연구 대상자들로부터 말초혈액 약 60-120 ml을 채취한 후, 2mM 의 EDTA와 인산완충용액이 들어있는 생리식염수로 1배씩 희석한 후, Ficoll-hypaque density gradient 방법을 통하여 말초혈액단핵세포(PBMC : peripheral blood mononuclear cell)을 분리하였다. Peripheral blood mononuclear cells (PBMCs) were obtained from the subjects by diluting them with 1 ml of physiological saline containing 2 mM EDTA and phosphate buffer solution, and then, using Ficoll-hypaque density gradient method, : peripheral blood mononuclear cells) were isolated.
MACS (Indirect magnetic labeling system, Miltenyi Biotec Inc, CA) Total CD4+ T 세포 isolation kit을 이용하여 말초혈액으로부터 분리한 PBMC에 biotin-conjugated antibody cocktail과 biotin micro-bead를 이용하여 non-CD4+ T 세포를 제거하는 원리로 total CD4+ T 세포를 얻었다(negative selection).
MACS using (Indirect magnetic labeling system, Miltenyi Biotec Inc, CA) Total CD4 + T cell isolation kit in a PBMC isolated from peripheral blood biotin-conjugated antibody cocktail and using the biotin micro-bead of non-CD4 + T cells Total CD4 + T cells were obtained by negative selection (negative selection).
<1-3> Total CD4<1-3> Total CD4 ++ T cell의 genomic DNA 분리 Isolation of genomic DNA from T cell
상기 CD4+ T cell 로부터 QAIGEN의 DNeasy Blood & Tissue kit(Cat. 69504, QIAGEN, 독일)을 이용하여 genomic DNA를 얻었다. 상기 Kit의 매뉴얼(Blood and body fluid spin protocol)에 따라 실험을 진행하였다. Proteinase K를 처리한 total CD4+ T 세포를 lysis buffer로 용해하고 Blood or Body Fluid Spin Protocol에 따라 실험을 진행한 뒤 샘플을 DNA spin column에 넣고 8000 rpm에서 원심분리 하였다. Column 에 흡착된 DNA를 washing buffer 로 씻은 후 elution buffer를 이용하여 분리하였다.Genomic DNA was obtained from the CD4 + T cell using the DNase Blood & Tissue kit (Cat. 69504, QIAGEN, Germany) of QAIGEN. Experiments were conducted according to the kit's manual (Blood and body fluid spin protocol). Proteinase K-treated total CD4 + T cells were lysed with lysis buffer and tested according to the Blood or Body Fluid Spin Protocol. The samples were placed in DNA spin columns and centrifuged at 8000 rpm. The DNA adsorbed on the column was washed with washing buffer and then separated with elution buffer.
정상인과 건선 및 아토피 환자군의 total CD4+ T 세포로부터 얻은 genomic DNA의 양을 측정한 결과 약 1,800 내지 20,000 ng 이었으며, purity (260/280)는 1.9 내지 2.1 정도로 측정되었다. 각각의 DNA를 1,500 ng 의 일정농도씩 pooling하여 실험에 사용하였다.
The amount of genomic DNA from normal CD4 + T cells in normal and psoriatic and atopic patients was measured to be about 1,800 to 20,000 ng and the purity (260/280) was measured to be about 1.9 to 2.1. Each DNA was pooled at a constant concentration of 1,500 ng and used for experiments.
<실시예 2>≪ Example 2 >
Total CD4Total CD4
++
T cell과 대조군의 DNA methylation 비교 Comparison of DNA methylation between T cell and control group
<2-1> 메틸화된 DNA의 선택적 분리<2-1> Selective separation of methylated DNA
메틸화된 DNA 선별을 위해 MIRA(Methylated CpG Island Recovery Assay)를 BMC Med Genomics. 2011 Dec 2;4:82, J Thorac Oncol. 2012 Jan;7(1):20-33.에 기재된 방법에 따라 실시하였다. 먼저 Genomic DNA의 TTAA 서열을 인식하여 자르는 제한효소 MseI (5’-TTAA)를 이용하여 CpG를 포함하지 않는 부위를 자르고, 잘려진 DNA fragment를 linker와 ligation 시켰다. 정제된 methylated DNA fragment를 GST-MBD2b와 His-MBD3L1 단백질과 결합시킨 후 비특이적 결합의 DNA는 없애고 RNase A(100 ug, Qiagen)와 Proteinase K(15ug, Qiagen)가 포함된 TE 버퍼(Tris-HCl-EDTA 버퍼) 30ul을 이용하여 결합된 DNA를 회수하였다.
Methylated CpG Island Recovery Assay (MIRA) was performed by BMC Med Genomics. 2011
<2-2> 분리된 DNA의 PCR 수행<2-2> PCR of isolated DNA
상기 회수한 DNA fragment를 linker primer(upper strand sequence, 5-TAGAATTCAGATCTCCCG-3 (서열번호 7), lower strand sequence, 3-CTTAAGTCTAGAGGGCCCAGTGGCG-5(서열번호 8))를 이용하여 PCR하여 linear amplification하였다. 증폭된 DNA를 겔 전기영동으로 분리하여 200-500 bp 정도의 DNA를 확인한 후, 겔 추출(gel extraction)을 통하여 분리하였다. 분리한 DNA는 Illumina GA sequencing (Illumina Inc. 미국)을 이용하여 Genome-wide 수준의 methylation을 분석하였다. Sequence tags 는 Solexa Analysis Pipeline (version 0.3.0)을 이용하여 the University of California Santa Cruz [UCSC, (http://genome.ucsc.edu)] hg18 database를 기초로 한 NCBI Build 36.1 assembly 의 human genome 에 mapping되었다. mapping 된 sequencing 결과는 UCSC Genome Browser에 호환되었고, 보다 구체적인 methylation 수치를 비교하기 위해, 읽혀진 sequencing data를 browser extensible data (BED) 로 변형하였다. 사용된 Tag distribution 은 Poisson distribution을 기초로 진행되었다(Park et al. BMC Medical Genomics 2011, 4:82; J Thorac Oncol. 2012;7: 203). The recovered DNA fragment was subjected to linear amplification by PCR using a linker primer (5-TAGAATTCAGATCTCCCG-3 (SEQ ID NO: 7), lower strand sequence, 3-CTTAAGTCTAGAGGGCCCAGTGGCG-5 (SEQ ID NO: 8)). The amplified DNA was separated by gel electrophoresis and DNA of about 200-500 bp was isolated and separated by gel extraction. The isolated DNA was analyzed for genome-wide methylation using Illumina GA sequencing (Illumina Inc. USA). Sequence tags were generated using the Solexa Analysis Pipeline (version 0.3.0) at the University of California Santa Cruz [UCSC, (http://genome.ucsc.edu)] in the human genome of the NCBI Build 36.1 assembly based on the hg18 database mapping. The mapping sequencing results are compatible with the UCSC Genome Browser. To compare more specific methylation values, we transformed the sequencing data into browser extensible data (BED). The Tag distribution used was based on the Poisson distribution (Park et al., BMC Medical Genomics 2011, 4:82; J Thorac Oncol. 2012; 7: 203).
하나의 DNA fragment를 200bp 마다 tagging 하여 유전자 부위별로 methylation 이 많은 부분에 tagging 이 많이 되도록 하였다. Methylation 이 많은 부위를 알아내기 위하여 1 kb 마다 mapping 된 DNA fragment 를 genome 안에서 전체 DNA fragment 수와 함께 비교하였다. methylation 정도를 비교하기 위한 값으로 Methylation Enrichment Score(MES)는 genome size (15005528*200 bp) 규모의 전체적인 methylation count 에 의해 조정되었으며, promoter 크기에 의해 (8*200 bp) 200 bp 간격으로 분할된 유전자 methylation count의 평균값을 log2 한 값으로 계산되었다. One DNA fragment was tagged every 200 bp, so that tagging was performed at a portion where methylation was high in a gene region. In order to identify the sites of methylation, the DNA fragments mapped per kb were compared with the total number of DNA fragments in the genome. Methylation Enrichment Score (MES) was adjusted by the total methylation count of genome size (15005528 * 200 bp) and was divided by the promoter size (8 * 200 bp) at 200 bp intervals The mean value of methylation count was calculated as log2.
Methylation Enrichment Score(MES)을 구하는 식은 다음과 같다.The Methylation Enrichment Score (MES) is obtained as follows.
dMES 는 얻어진 환자의 MES 값에서 정상인의 MES 값을 뺀 것으로, 특정 유전자에서 건선 환자군과 정상인군의 methylation 수치의 차이를 나타낸다.
dMES is obtained by subtracting the MES value of the normal person from the MES value of the obtained patient, and shows the difference in the methylation level between the psoriasis patient group and the normal person group in the specific gene.
<2-3> 메틸화 비교 결과<2-3> Comparison of methylation results
1) Genome-wide 분석1) Genome-wide analysis
건선과 아토피 각각의 dMES 값을 이용하여 메틸화 차이를 비교해보았다. 게놈 전체를 10kbp 간격으로 나눈 다음, dMES 값을 평균 내었다.We compared the differences in methylation using dMES values of psoriasis and atopy. The entire genome was divided by 10 kbp intervals, and the dMES values were averaged.
상기 결과는 [도 1]에 기재하였는데, [도 1]에서 건선 환자의 경우, 정상 대조군보다 일정부분에서 메틸화가 눈에 띄게 높아진 것을 확인할 수 있다. 건선환자의 Total CD4+ T cell의 DNA에서 과메틸화(hypermethylation) 변화를 보인 부위를 분색해 본 결과, 총 866 군데의 부위에서 그러한 변화가 있었고, 이중 유전자 부위를 포함하는 부위도 존재하였다. 그러나 아토피 환자는 특이적인 메틸화 변화가 없었다. 상기 건선환자에서 발견되는 과메틸화 된 866개의 부위는 아래 [표 1]에 기재하였고, 상기 과메틸화된 부분에 포함된 유전자는 아래 [표 2]에 기재하였다.The above results are shown in Fig. 1, but in the case of psoriasis patients in Fig. 1, it can be seen that the methylation is remarkably higher in a certain region than the normal control group. In the total CD4 + T cells of patients with psoriasis, there was a change in the hypermethylation region of the DNA, resulting in a total of 866 such changes. However, there was no specific methylation change in atopic patients. The 866 hypermethylated regions found in the patients with psoriasis are listed in Table 1 below, and the genes included in the hypermethylated regions are listed in Table 2 below.
endPosition
end
startPosition
start
endPosition
end
MES(Psoriasis-Normal)
MES
2) 유전자 단위 분석2) Analysis of gene unit
좀 더 구체적인 결과를 얻기 위하여, 유전자단위로 methylation 변화를 알아보았다. 건선과 아토피 각각 염색체별로 promoter 와 gene body 의 methylation 변화를 살펴보았다.In order to obtain more specific results, methylation changes were investigated by gene unit. We examined the methylation changes of promoter and gene body for each chromosome of psoriasis and atopy.
상기 결과는 [도 2]에서 기재하였는데, [도 2]에서 건선 환자의 Total CD4+ cell DNA 프로모터와 genebody 부분이 정상 환자보다 과메틸화되어 있음을 확인할 수 있다. 아토피 환자는 genome-wide 분석과 마찬가지로, 특이적인 메틸화 변화가 없었다. The results are shown in FIG. 2, which shows that the total CD4 + cell DNA promoter and the genebody portion of psoriasis patients were over-methylated. As with genome-wide analysis, atopic patients did not have any specific methylation changes.
상기 건선 환자의 Total CD4+ T cell에서 과메틸화된 프로모터 중 dMES 값이 1 이상(정상과 비교하여 2배 더 메틸화가 증가한 경우)인 유전자를 확인해본 결과, 430개의 유전자를 얻을 수 있었으며, 발견된 유전자 중 CpG island(CpGI)를 가지고 있는 유전자는 217개, 갖고 있지 않는 유전자는 213개임을 확인하였다. 상기 발견된 430개의 유전자를 아래 [표 3]에 기재하였다.In the total CD4 + T cell of patients with psoriasis, 430 genes were obtained when the dMES value of the hypermethylated promoter was 1 or more (2-fold increase in methylation compared with normal) (CpGI) was found in 217 genes and 213 genes in CpG island. The 430 genes found above are listed in Table 3 below.
startPosition
start
endPosition
end
MESPsoriasis
MES
MESNormal
MES
MES(Psoriasis-Normal)
MES
<실시예 3>≪ Example 3 >
mRNA 발현 비교mRNA Expression Comparison
메틸화 된 유전자는 mRNA 발현 수준이 낮을 것으로 예상되어, 상기 [표 2] 및 [표 3]에서 나열된 유전자 중 임의로 TP73([표 3]의 no.1), FANK1([표 3]의 no. 176), PPAPDC3([표 3]의 no. 156)을 택하여, 정상군과 건선군에서 mRNA 발현을 비교해보았다. 또한 DNA methylation inhibitor로 처리한 실험을 추가하여, 재확인을 해보았다.The methylated gene is expected to have a low level of mRNA expression, and thus, TP73 (no.1 in [Table 3]), FANK1 (no. 176 in [Table 3]) among the genes listed in [Table 2] ) And PPAPDC3 (no. 156 in [Table 3]), and compared mRNA expression in the normal group and in the dry eye group. In addition, we have re-confirmed DNA methylation inhibitor-treated experiments.
DNA methylation inhibitor로 처리한 실험군을 만들기 위해, 실시예 <1-2>에서 분리한 건선환자의 total CD4+ T cell을 1x106/ml의 농도로 IL-2(100 IU/ml)가 포함된 RPMI(10% FBS)에서 배양한다. 이때 DNA methylation inhibitor인 5-azacytidine 을 10 uM로 처리한 다음 24시간 또는 48시간 동안 incubation 한 뒤, 세포를 모아 RNA 를 뽑았다.To construct an experimental group treated with DNA methylation inhibitor, the total CD4 + T of the psoriasis patients isolated in Example < 1-2 > cells are cultured in RPMI (10% FBS) containing IL-2 (100 IU / ml) at a concentration of 1x10 6 / ml. At this time, 5-azacytidine, a DNA methylation inhibitor, was treated with 10 μM and incubated for 24 hours or 48 hours. Cells were collected and RNA was extracted.
QuantiTect Rev. Transcription Kit(QIAGEN)을 이용하여 분리한 RNA를 cDNA로 제작한 다음 real-time PCR을 시행하였다. KAPA SYBRFAST qPCR Kits을 이용하여 Rotergene 6000 (Corbett, Australia)에서 시행하였다. PCR 프로그램은 95°C 에서 10분 동안 1 cycle, 95℃ 에서 20초, 55℃에서 20초, 72℃에서 20초간 40 cycle을 시행하여 Delta-Delta CT 방법으로 결과를 수치화시켰다. 각각의 loading control 로 glyceraldehyde-3-phosphate dehydrogenase를 사용하였다. QuantiTect Rev. Transcription Kit (QIAGEN) was used to generate cDNA from the isolated RNA and then real-time PCR was performed. KAPA SYBRFAST qPCR Kits were performed on a Rotergene 6000 (Corbett, Australia). PCR was performed by Delta-Delta CT method at 95 ° C for 10 minutes, at 95 ° C for 20 seconds, at 55 ° C for 20 seconds, and at 72 ° C for 20 seconds for 40 cycles. Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control.
건선군 1(5-azacytidine 비처리군), 건선군 2(5-azacytidine 처리군)의 실험결과는 Rotergene 6000 (Corbett, Australia) 프로그램의 Delta-Delta CT 방법으로 수치화 되었다. 각 결과에 대한 유의성을 체크하기 위하여 T-TEST 방법을 사용하였다.Experimental results of group 1 (5-azacytidine untreated) and group 2 (5-azacytidine treated) were quantified using the Delta-Delta CT method of the Rotergene 6000 (Corbett, Australia) program. The T-test method was used to check the significance of each result.
증폭에 사용한 프라이머 정보는 아래 [표 4]에 표시하였다.The primer information used for amplification is shown in Table 4 below.
TP73
148 bp
FANK1
135 bp
PPAPDC3
141 bp
정상군과 건선 환자 군에서 상기 세 유전자의 mRNA 발현 수준은 [도 3]의 A에 기재하였고, 건선 환자군의 total CD4+ T cell에 5-azacytidine 처리한 군과 비처리군 간의 mRNA 발현 수준은 [도 3]의 B에 기재하였다. [도 3]의 A에서 정상군에 비해 건선 환자군에서 상기 세 유전자의 mRNA 발현이 유의적으로 감소함을 확인할 수 있고, [도 3]의 B에서 5-azacytidine 처리군의 경우, 상기 세 유전자의 mRNA 발현이 증가하였음을 알 수 있다. 따라서 건선 진단은 [표 2] 또는 [표 3]에 나열한 유전자들의 mRNA 발현 수준으로 진단할 수 있음을 알 수 있다.
The mRNA expression levels of the three genes in the normal group and the psoriasis group are shown in [A] of FIG. 3, and the total mRNA expression level of 5-azacytidine treated group and the untreated group in the total CD4 + 3]. 3 in Fig. 3, mRNA expression of the three genes was significantly reduced in the psoriasis group compared to the normal group, and in the case of 5-azacytidine treatment group in Fig. 3B, mRNA expression was increased. Thus, psoriasis diagnosis can be diagnosed by the mRNA expression level of the genes listed in [Table 2] or [Table 3].
<실시예 4><Example 4>
프로모터의 활성화와 메틸화의 관계Relationship between Activation and Methylation of Promoters
<4-1> 메틸화된 ≪ 4-1 > TP73TP73 유전자의 프로모터 부위별 활성화 측정 Activation of gene by promoter region
메틸화 된 유전자의 프로모터 부위를 클로닝하여 그 활성화를 측정하는 방법이다. CD4+ T 세포의 Genomic DNA에서 PCR 방법을 이용해 TP73 유전자의 약 1 kb upstream 부위를 루시퍼라제 유전자의 앞 쪽에 위치시킬 수 있게 클로닝을 한다. 즉 프로모터의 작용에 따른 루시퍼라제의 활성화를 측정함으로써 프로모터의 기능을 판단한다. The promoter region of the methylated gene is cloned and its activation is measured. In the CD4 + T cell genomic DNA, cloning is carried out using the PCR method to locate about 1 kb upstream of the TP73 gene in front of the luciferase gene. That is, the function of the promoter is determined by measuring the activation of luciferase according to the action of the promoter.
Transformed T cell line인 Jurkat T cell을 RPMI (10% FBS)에서 4x105/ml의 농도로 배양하고 여기에 프로모터가 클로닝된 벡터 1 microgram과 lipofectamine 2000 transfection reagent 3 microlitter를 섞은 혼합물을 처리하여 세포에 transfection 시킨다. 이 후 48시간이 지난 후 세포를 모아서 promega 회사의 dual luciferase assay system에서 제공하는 세포 용해 버퍼와 시약들을 이용하여 활성화를 측정한다. 활성 측정 기계는 luminometer를 이용한다. (도4 A)Transformed T cell line Jurkat T cells were cultured in RPMI (10% FBS) at a concentration of 4 × 10 5 / ml and treated with a mixture of 1 microgram of the vector in which the promoter was cloned and lipofectamine 2000
대조 벡터의 활성을 기준으로 상대적 활성도를 측정하여 나타내고, 프로모터의 부위별 활성도를 측정하기 위해, 추가적으로 연속적 결손을 일으킨 프로모터 부위를 클로닝하여 그 활성도를 측정한다. 이 방법은 프로모터의 부위별 활성 정도를 알 수 있게 하는 방법으로 각 부위의 활성 기여도를 측정할 수 있다. (도4 A)
The relative activity is measured and expressed based on the activity of the control vector. In order to measure the activity of each region of the promoter, the promoter region that has been further sequenced is cloned and its activity is measured. This method can measure the active contribution of each site in such a way that the degree of activity of each part of the promoter can be known. (Figure 4A)
<4-2> 메틸화로 인한 프로모터 활성 감소<4-2> Reduction of promoter activity due to methylation
루시퍼라제 활성화 측정으로 확인된 프로모터 클로닝 벡터를 대상으로 in vitro 메틸화를 시킨 후 활성도를 측정하여 메틸화의 효과를 측정하는 방법이다.The in vitro methylation of a promoter cloning vector identified by luciferase activation assay, followed by measurement of the activity, measures the effect of methylation.
대조 벡터와 TP73 포로모터 (-438 ~ +53) 부위가 클로닝된 벡터를 대상으로 CpG 메틸레아제인 M.SssI 효소를 이용하여 S-adenosyl methionine (SAM)을 메틸기 공급 물질로 벡터들을 메틸레이션 시킨다. 반응 후 메틸레이션에 민감한 제한 효소 (예; NotI)를 이용하여 메틸레이션 정도를 확인하고 메틸레이션 시키지 않은 벡터와 함께 정제 과정을 거쳐 정량을 한 후 실험에 이용한다.Vectors were methylated with S-adenosyl methionine (SAM) as a methyl group-supplying substance using a CpG methylase, M.SssI enzyme, as a control vector and a vector in which a TP73 captor motor (-438 to +53) region was cloned. After the reaction, the degree of methylation is checked using a restriction enzyme sensitive to methylation (eg, NotI), and the resultant is subjected to purification through a purification process with a vector not subjected to methylation.
메틸레이션 시킨 벡터들을 대조군과 함께 Jurkat T 세포에 위와 같은 방법으로 transfection 시킨 후 루시퍼라제 측정을 통해 프로모터 부위의 메틸레이션 유무에 따른 활성화를 비교하여 그 효과를 검증한다.(도4 B)
The methylated vectors were transfected with Jurkat T cells together with the control group in the same manner as described above, and then the activation of the promoter region with and without methylation was checked by luciferase assay to verify the effect (FIG. 4B)
본 발명의 TP73(GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) 및 PPAPDC3(GenBank Accession No. NM_032728)로 이루어진 군에서 선택되는 어느 하나의 유전자를 이용한 건선 진단에 필요한 정보를 제공하는 방법, 건선 진단용 조성물 및 진단용 키트를 제공한다. 본 발명의 방법, 조성물 및 키트를 이용하여 건선 질환을 진단할 수 있어, 산업상 이용가능성이 높다. A method for providing information necessary for the diagnosis of psoriasis using any one gene selected from the group consisting of TP73 (GenBank Accession No. NM_001126240), FANK1 (GenBank Accession No. NM_145235) and PPAPDC3 (GenBank Accession No. NM_032728) A composition for diagnosing psoriasis, and a diagnostic kit. The methods, compositions and kits of the present invention can be used to diagnose psoriasis and are highly industrially applicable.
<110> CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
<120> Genetic Marker for Diagnosis of Psoriasis and Method for
diagnosis of Psoriasis using the same
<130> NP12-0080
<160> 11
<170> KopatentIn 2.0
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for TP73
<400> 1
cagatccatg cctcgtcc 18
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for TP73
<400> 2
ctgctcatct ggtccatgg 19
<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for FANK1
<400> 3
agtggttcag gttctcgatt g 21
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for FANK1
<400> 4
tgaccttcag gcgaaatctg 20
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for PPAPDC3
<400> 5
aggtgctcat gaatctgctc 20
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for PPAPDC3
<400> 6
ggaaggcgta gatgtccatg 20
<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Linker primer for upper strand sequence
<400> 7
tagaattcag atctcccg 18
<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Linker primer for lower strand sequence
<400> 8
gcggtgaccc gggagatctg aattc 25
<210> 9
<211> 5131
<212> DNA
<213> TP73 gene sequence of Homo sapiens
<400> 9
ggattcagcc agttgacaga actaagggag atgggaaaag cgaaaatgcc aacaaacggc 60
ccgcatgttc cccagcatcc tcggctcctg cctcactagc tgcggagcct ctcccgctcg 120
gtccacgctg ccgggcggcc acgaccgtga cccttcccct cgggccgccc agatccatgc 180
ctcgtcccac gggacaccag ttccctggcg tgtgcagacc ccccggcgcc taccatgctg 240
tacgtcggtg accccgcacg gcacctcgcc acggcccagt tcaatctgct gagcagcacc 300
atggaccaga tgagcagccg cgcggcctcg gccagcccct acaccccaga gcacgccgcc 360
agcgtgccca cccactcgcc ctacgcacaa cccagctcca ccttcgacac catgtcgccg 420
gcgcctgtca tcccctccaa caccgactac cccggacccc accactttga ggtcactttc 480
cagcagtcca gcacggccaa gtcagccacc tggacgtact ccccgctctt gaagaaactc 540
tactgccaga tcgccaagac atgccccatc cagatcaagg tgtccacccc gccaccccca 600
ggcaccgcca tccgggccat gcctgtttac aagaaagcgg agcacgtgac cgacgtcgtg 660
aaacgctgcc ccaaccacga gctcgggagg gacttcaacg aaggacagtc tgctccagcc 720
agccacctca tccgcgtgga aggcaataat ctctcgcagt atgtggatga ccctgtcacc 780
ggcaggcaga gcgtcgtggt gccctatgag ccaccacagg tggggacgga attcaccacc 840
atcctgtaca acttcatgtg taacagcagc tgtgtagggg gcatgaaccg gcggcccatc 900
ctcatcatca tcaccctgga gatgcgggat gggcaggtgc tgggccgccg gtcctttgag 960
ggccgcatct gcgcctgtcc tggccgcgac cgaaaagctg atgaggacca ctaccgggag 1020
cagcaggccc tgaacgagag ctccgccaag aacggggccg ccagcaagcg tgccttcaag 1080
cagagccccc ctgccgtccc cgcccttggt gccggtgtga agaagcggcg gcatggagac 1140
gaggacacgt actaccttca ggtgcgaggc cgggagaact ttgagatcct gatgaagctg 1200
aaagagagcc tggagctgat ggagttggtg ccgcagccac tggtggactc ctatcggcag 1260
cagcagcagc tcctacagag gccgagtcac ctacagcccc cgtcctacgg gccggtcctc 1320
tcgcccatga acaaggtgca cgggggcatg aacaagctgc cctccgtcaa ccagctggtg 1380
ggccagcctc ccccgcacag ttcggcagct acacccaacc tggggcccgt gggccccggg 1440
atgctcaaca accatggcca cgcagtgcca gccaacggcg agatgagcag cagccacagc 1500
gcccagtcca tggtctcggg gtcccactgc actccgccac ccccctacca cgccgacccc 1560
agcctcgtca gttttttaac aggattgggg tgtccaaact gcatcgagta tttcacctcc 1620
caagggttac agagcattta ccacctgcag aacctgacca ttgaggacct gggggccctg 1680
aagatccccg agcagtaccg catgaccatc tggcggggcc tgcaggacct gaagcagggc 1740
cacgactaca gcaccgcgca gcagctgctc cgctctagca acgcggccac catctccatc 1800
ggcggctcag gggaactgca gcgccagcgg gtcatggagg ccgtgcactt ccgcgtgcgc 1860
cacaccatca ccatccccaa ccgcggcggc ccaggcggcg gccctgacga gtgggcggac 1920
ttcggcttcg acctgcccga ctgcaaggcc cgcaagcagc ccatcaagga ggagttcacg 1980
gaggccgaga tccactgagg gcctcgcctg gctgcagcct gcgccaccgc ccagagaccc 2040
aagctgcctc ccctctcctt cctgtgtgtc caaaactgcc tcaggaggca ggaccttcgg 2100
gctgtgcccg gggaaaggca aggtccggcc catccccagg cacctcacag gccccaggaa 2160
aggcccagcc accgaagccg cctgtggaca gcctgagtca cctgcagaac cttctggagc 2220
tgccctagtg ctgggcttgt ggggcggggg ctggcccact ctcagccctg ccactgcccc 2280
ggcgtgctcc atggcaggcg tgggtgggga ccgcagcgtc ggctccgact tccaggcttc 2340
atcctagaga ctgtcatctc ccaaccaggc gaggtccttc caaaggaaag gatcctcttt 2400
gctgatggac tgccaaaaag tattttgcga catcttttgg ttctggatag tagtgagcag 2460
ccaagtgact gtgtctgaaa caccagtgta ttttcaggga atgtccctaa ctgcgtcttg 2520
cccgcgccgg gggctgggga ctctctctgc tggacttggg actggcctct gcccccagca 2580
cgctgtattc tgcaggaccg cctccttcct gcccctaaca acaaccacag tgttgctgaa 2640
attggagaaa actggggagg gcgcaacccc ccccaggcgc ggggaagcat gtggtaccgc 2700
ctcagccagt gcccctcagc ctggccacag tcgcctctcc tcggggaccc ctcagcagaa 2760
agggacagcc tgtccttaga ggactggaaa ttgtcaatat ttgataaaat gatacccttt 2820
tctacatggt gggtcagctt tttttttttt ttttttaact ttctttctca gcattctctt 2880
tggagttcaa cctagcgccc atgagccagg ctgaggaagc tgagtgagaa gccaggtggg 2940
cgggacttgt tcccaggaag gccgggtggg gaggaagcct agagggaacc ccaggaaggg 3000
caaatccagg caaatctgca ggaatgctct gccatgggag cagctcctcc cttgccacgg 3060
ccaccttctc tagcactgca aggtccacag ggcattgctt tcctttctag gcggtggcag 3120
tcagggaaca gactgaggta ggtgtagggg ggtctaggcc ttcgtggagc accccaggga 3180
gttagtaggc cccggggaga cagagtctgc acaggccctt tctggggcca cctccatcca 3240
cgaggagcag cctgagcctt ggtggccgaa ccttgaccgt cccggagcac agcttcaggg 3300
cagggaaccg gagcccctgg ggggcctcac gggtgtgacg aggcccttca ttgcaggcag 3360
gtgggccaat gggagccctc acccacgcaa gccgagacac cacccagagt gcaggctgcc 3420
tggccccttc tggcacggcc agctccacac cccctgccta gggtatgtgt ggtcctaagg 3480
gctaggagct tcccctacta acatctccca gaaaaagcag ttaagcccct cagggcacag 3540
caaggttaga cacagccccc atccccagat caggactcca tcttgctaag tggcatcacc 3600
gtcaccagcc tccccttatt taaaagcagc gactggtgtt gccgcaggta cctggtctac 3660
gaagacgcag gcatccctct cccaccgtcc acctccccgg gggccgctga cagcacagtc 3720
gcctgggtgc acgcttgtgg gggcagcagg aacggggctg tcggctctca ggggatctgg 3780
ctgcagccag ggcgagggcc tggcccttcc ttccagctcc ttccggctcc ttccagctga 3840
agggcaggaa gctctggccg cttagcttct agggttccat ctccctagaa aggtgcccac 3900
gcccagggca tcagtcagta gcggcagcag cagcagactc ggggctttcc cagggtggcg 3960
cagccacccc agctgcatgt cacctcagct ctccatctta ttgccatttt gtagatgagg 4020
aagctgagac cagaaaggct aagacccatg ccccaggcac cacacccatc tcttgggggc 4080
tgggcacctg ctacccgagg ccacctcctg aagcccccac tcttccccca tgttccactt 4140
caggagccgc gggggcccat cctgacaccc ggggttcctc agcccagcgc agatgtgctt 4200
cagttccaga gggcttgttg atttgtttct taggtacgtt acctgtccac cctgagtcca 4260
gtgaggctgt cccaagagcc cctgtagtgt gctcctggga agggctgggg gggctggggg 4320
ggctgggaga ggcccagggg cagctgtcac tggaacccca gccagatgtc caaggaagcc 4380
ggccagaaca cggagcagcc agatggcccc agctgcacct gtctagggag cccatgcagc 4440
ctccttgcac tggagaagca gctgtgaaag tagacagagt tgagacttcg ccgtggtcag 4500
gagaaaatgc aaattcccag gaacaagaat cctttaagtg atatgttttt ataaaactaa 4560
acaaatcaac aaataaatct tgaaggcgga tggttttccc agcagtgcag gggttggagg 4620
gaggctgctg gcactcctgg ggccaagggg gacaggcagt ggtcctgagt ctgctcagag 4680
aggcaaggca gaaggagctc gccaggcagg tcagctcaca tctgtccaag tcgctctggt 4740
cagaaacagc gactctcccc cattccccca gcgttcccac caggcctggg ctgctgggaa 4800
gcccttgctg tacccaggag cccgacccgc agtatcctgg cacagagcca cttgtcactc 4860
agaacagtca gtgtctccaa cgcacaaaca tccactcctc tgttaccagt taaagcactt 4920
taatgcttta aggtgaaaac gaaatcccat ccgtgttttt cgtgtaagat cgtgcttctc 4980
cgagcagtat taatggacgc cctccaatga cataacaact gtttttggta atgtaatctt 5040
gggaaaatgt gttatttttt tagctgtgtt tcagtgggga tttttgtttt tgtaacataa 5100
taaagtgtat gttccaatga aaaaaaaaaa a 5131
<210> 10
<211> 1395
<212> DNA
<213> FANK 1 gene sequence of Homo sapiens
<400> 10
cacttcgcct ccgggttgtc agggcaaccg tagcgacgcc ggccctggct gagaggcgtt 60
aggagtccgg gggttcgccc gcggaggccg gggagcagcc gaccatggag ccccagaaaa 120
tcatgccacc ctcaaagcct catccacctg tcgtgggcaa agtgactcat cacagcattg 180
aattatactg ggatctggaa aagaaagcca aacgccaagg acctcaagag cagtggttca 240
ggttctcgat tgaagaagaa gaccccaaaa tgcacactta tggtatcatt tatacgggat 300
atgcaacgaa gcatgttgtt gaaggtctgg aaccaaggac gctgtacaga tttcgcctga 360
aggtcaccag cccctctggg gagtgtgagt acagcccact cgtctcagtg tctacaacca 420
gagagcccat aagtagtgag cacttgcacc gggctgtcag tgtgaatgat gaagatttgc 480
tggtccgaat acttcaagga ggccgtgtta aggttgatgt tcccaataag tttggcttta 540
ccgctctgat ggttgctgcc cagaaaggat acaccaggct tgtgaaaatc ctagtttcta 600
atggcacaga cgtgaatctg aagaatggaa gtggcaagga cagtctaatg ctggcgtgct 660
atgcgggaca cctagatgtt gtgaaatatc tccgaagaca tggcgcttct tggcaggcta 720
gagacctggg aggctgtaca gctctgcact gggctgcaga tggaggccac tgcagtgtga 780
ttgagtggat gataaaggat ggctgtgagg tagacgtcgt ggacactggt tcaggatgga 840
ccccactcat gagagtctct gcggtgtcgg gaaatcagag ggtggcctct cttctaattg 900
atgctggggc caatgtgaat gtgaaggaca gaaatggaaa gacgcccctt atggtggctg 960
tgttaaataa tcatgaagag ttagttcagt tacttcttga caaaggggca gatgcaagtg 1020
taaaaaatga gttcggcaaa ggtgtcctag aaatggccag agtttttgac agacagagtg 1080
tagtctcctt attagaagaa aggaaaaaaa agcagaggcc aaagaagtct tgtgtctgct 1140
gatgagagca ccactcatct gcgaaacgca cgtaaaacaa agtgaaccgt gactgttaaa 1200
ctagggatgg gaaattctgc atcttggggg gctgtacatt tatttattta gttgaagatt 1260
cactgatccc actttgaaat acatcttttt acctaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aaaaa 1395
<210> 11
<211> 2095
<212> DNA
<213> PPAPDC3 gene sequence of Homo sapiens
<400> 11
aaatagccca ggcccgaggc agccaggccg cagctgtgga ctcctcacct cccggaggct 60
ctgctggtgc aggccccgca ttggagggct cgattggctg cccggctggc actgacgtcc 120
ccttggagct gggtggcaga ggagataaac agccatgtgc aactctccac actatattta 180
acagctgcgg cggagaaggc agggaggcag ccacggtggc ggctctgggg gcagctcttg 240
tcttcgggga gaaggccctt ggagccgggc tggcatcggc cttctcgggg tgagcgaggt 300
caccatgcca gcttcccaga gccgggcccg tgcccgggac cgcaacaacg tcctcaaccg 360
ggctgagttc ctgtccctga accagccccc caaggggggc ccggagcccc gcagctcggg 420
cagaaaggcc tcgggcccat cagcacagcc cccacctgct ggtgacgggg ccagagagcg 480
acgccagtca cagcagctgc cagaggagga ctgcatgcag ctgaacccct ccttcaaggg 540
catcgccttc aactccctgc tggccatcga tatctgtatg tccaagcggc tgggggtgtg 600
cgctggccgg gcggcgtcct gggccagtgc ccgctccatg gtcaagctca tcggcatcac 660
gggccacggc atcccctgga tcggaggcac catcctctgc ctggtgaaga gcagcacact 720
ggccggccag gaggtgctca tgaatctgct cctggccctg ctcctggaca tcatgacggt 780
ggccggcgtg cagaagctca tcaagcggcg cggcccgtac gagacgagcc ccagcctcct 840
ggactacctc accatggaca tctacgcctt cccggccggg cacgccagcc gcgccgccat 900
ggtgtccaag ttcttcctca gccacctggt gctggcggtg cccctgcgtg tgctgctggt 960
gctctgggcc ctctgcgtgg gcctgtcccg cgtgatgatc ggccgccacc acgtcacgga 1020
cgtcctctcc ggctttgtca tcggctacct ccagttccgt ctggtggagc tggtctggat 1080
gccctccagc acctgccaga tgctcatctc tgcctggtga agcgcccgcc ggcccacaca 1140
agcctctggg ggcagggctg gccctagaga aggggcaggg ggtggcgagg tggcgggcgt 1200
gggtggaaca gagcggccag gagtcagagc ggccaccccc acctcatctt cccctcctgg 1260
ctggaggctg gcgaacccag gccacccctc ccggagacaa gcgtgtttgg cagtgccagg 1320
cctcttgccc ctttgcttgg actccaagtc tcctctctag gcagccagga cccacccatg 1380
gggacagccc tatttagctt ctgctctggg aacagcaaaa atcaggatgg tgggaggggc 1440
cgagtcttgt cttgtccttt catcatcatg actgttgagt tcttggctgt gcccatcacg 1500
ccacagcacg acgcctgcca aaatgccccc aacctactgc ctgatgcagg tgccattgcc 1560
attagcggtc atcgacagct tagggcagca ctttccaacg ggtgcccatg ggacaccagc 1620
ctgcgagatg cttttggggg aaaggggttt tgtggttcaa taactttcgg aagtgctgca 1680
cactctgtcc ccaagttgga cattcacaaa ggccgttatt gccgtaaagg ctctgacaag 1740
ccctatagaa aagcttcttg ctaaaccttc tttaacccat gttttctaaa cttatttgac 1800
cacagaaccc ttttcttggg gaacagctat taacccccaa ggaattattg gttcctcaag 1860
tgcgttttgg gagctgctgc cagagagcta aagggcctgg ggtgtgagct gactctcctc 1920
tggggaggcc gggtgcacac gccacagccc gaggaaagtg ctggccaccg cccgtgggca 1980
tcgatgaggc tttggccccc aggggccgga ctccgtgtga cctaataggt cgtttccaag 2040
tcacccgttt tggatgtgca tttcatgtga caatacagat gacatgcaaa tggcc 2095
<110> CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
<120> Genetic Marker for Diagnosis of Psoriasis and Method for
diagnosis of Psoriasis using the same
<130> NP12-0080
<160> 11
<170> Kopatentin 2.0
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for TP73
<400> 1
cagatccatg cctcgtcc 18
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for TP73
<400> 2
ctgctcatct ggtccatgg 19
<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for FANK1
<400> 3
agtggttcag gttctcgatt g 21
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for FANK1
<400> 4
tgaccttcag gcgaaatctg 20
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Foward Primer for PPAPDC3
<400> 5
aggtgctcat gaatctgctc 20
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse Primer for PPAPDC3
<400> 6
ggaaggcgta gatgtccatg 20
<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Linker primer for upper strand sequence
<400> 7
tagaattcag atctcccg 18
<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Linker primer for lower strand sequence
<400> 8
gcggtgaccc gggagatctg aattc 25
<210> 9
<211> 5131
<212> DNA
<213> TP73 gene sequence of Homo sapiens
<400> 9
ggattcagcc agttgacaga actaagggag atgggaaaag cgaaaatgcc aacaaacggc 60
ccgcatgttc cccagcatcc tcggctcctg cctcactagc tgcggagcct ctcccgctcg 120
gtccacgctg ccgggcggcc acgaccgtga cccttcccct cgggccgccc agatccatgc 180
ctcgtcccac gggacaccag ttccctggcg tgtgcagacc ccccggcgcc taccatgctg 240
tacgtcggtg accccgcacg gcacctcgcc acggcccagt tcaatctgct gagcagcacc 300
atggaccaga tgagcagccg cgcggcctcg gccagcccct acaccccaga gcacgccgcc 360
agcgtgccca cccactcgcc ctacgcacaa cccagctcca ccttcgacac catgtcgccg 420
gcgcctgtca tcccctccaa caccgactac cccggacccc accactttga ggtcactttc 480
cagcagtcca gcacggccaa gtcagccacc tggacgtact ccccgctctt gaagaaactc 540
tactgccaga tcgccaagac atgccccatc cagatcaagg tgtccacccc gccaccccca 600
ggcaccgcca tccgggccat gcctgtttac aagaaagcgg agcacgtgac cgacgtcgtg 660
aaacgctgcc ccaaccacga gctcgggagg gacttcaacg aaggacagtc tgctccagcc 720
agccacctca tccgcgtgga aggcaataat ctctcgcagt atgtggatga ccctgtcacc 780
ggcaggcaga gcgtcgtggt gccctatgag ccaccacagg tggggacgga attcaccacc 840
atcctgtaca acttcatgtg taacagcagc tgtgtagggg gcatgaaccg gcggcccatc 900
ctcatcatca tcaccctgga gatgcgggat gggcaggtgc tgggccgccg gtcctttgag 960
ggccgcatct gcgcctgtcc tggccgcgac cgaaaagctg atgaggacca ctaccgggag 1020
cagcaggccc tgaacgagag ctccgccaag aacggggccg ccagcaagcg tgccttcaag 1080
cagagccccc ctgccgtccc cgcccttggt gccggtgtga agaagcggcg gcatggagac 1140
gaggacacgt actaccttca ggtgcgaggc cgggagaact ttgagatcct gatgaagctg 1200
aaagagagcc tggagctgat ggagttggtg ccgcagccac tggtggactc ctatcggcag 1260
cagcagcagc tcctacagag gccgagtcac ctacagcccc cgtcctacgg gccggtcctc 1320
tcgcccatga acaaggtgca cgggggcatg aacaagctgc cctccgtcaa ccagctggtg 1380
ggccagcctc ccccgcacag ttcggcagct acacccaacc tggggcccgt gggccccggg 1440
atgctcaaca accatggcca cgcagtgcca gccaacggcg agatgagcag cagccacagc 1500
gcccagtcca tggtctcggg gtcccactgc actccgccac ccccctacca cgccgacccc 1560
agcctcgtca gttttttaac aggattgggg tgtccaaact gcatcgagta tttcacctcc 1620
caagggttac agagcattta ccacctgcag aacctgacca ttgaggacct gggggccctg 1680
aagatccccg agcagtaccg catgaccatc tggcggggcc tgcaggacct gaagcagggc 1740
cacgactaca gcaccgcgca gcagctgctc cgctctagca acgcggccac catctccatc 1800
ggcggctcag gggaactgca gcgccagcgg gtcatggagg ccgtgcactt ccgcgtgcgc 1860
cacaccatca ccatccccaa ccgcggcggc ccaggcggcg gccctgacga gtgggcggac 1920
ttcggcttcg acctgcccga ctgcaaggcc cgcaagcagc ccatcaagga ggagttcacg 1980
gaggccgaga tccactgagg gcctcgcctg gctgcagcct gcgccaccgc ccagagaccc 2040
aagctgcctc ccctctcctt cctgtgtgtc caaaactgcc tcaggaggca ggaccttcgg 2100
gctgtgcccg gggaaaggca aggtccggcc catccccagg cacctcacag gccccaggaa 2160
aggcccagcc accgaagccg cctgtggaca gcctgagtca cctgcagaac cttctggagc 2220
tgccctagtg ctgggcttgt ggggcggggg ctggcccact ctcagccctg ccactgcccc 2280
ggcgtgctcc atggcaggcg tgggtgggga ccgcagcgtc ggctccgact tccaggcttc 2340
atcctagaga ctgtcatctc ccaaccaggc gaggtccttc caaaggaaag gatcctcttt 2400
gctgatggac tgccaaaaag tattttgcga catcttttgg ttctggatag tagtgagcag 2460
ccaagtgact gtgtctgaaa caccagtgta ttttcaggga atgtccctaa ctgcgtcttg 2520
cccgcgccgg gggctgggga ctctctctgc tggacttggg actggcctct gcccccagca 2580
cgctgtattc tgcaggaccg cctccttcct gcccctaaca acaaccacag tgttgctgaa 2640
attggagaaa actggggagg gcgcaacccc ccccaggcgc ggggaagcat gtggtaccgc 2700
ctcagccagt gcccctcagc ctggccacag tcgcctctcc tcggggaccc ctcagcagaa 2760
agggacagcc tgtccttaga ggactggaaa ttgtcaatat ttgataaaat gatacccttt 2820
tctacatggt gggtcagctt tttttttttt ttttttaact ttctttctca gcattctctt 2880
tggagttcaa cctagcgccc atgagccagg ctgaggaagc tgagtgagaa gccaggtggg 2940
cgggacttgt tcccaggaag gccgggtggg gaggaagcct agagggaacc ccaggaaggg 3000
caaatccagg caaatctgca ggaatgctct gccatgggag cagctcctcc cttgccacgg 3060
ccaccttctc tagcactgca aggtccacag ggcattgctt tcctttctag gcggtggcag 3120
tcagggaaca gactgaggta ggtgtagggg ggtctaggcc ttcgtggagc accccaggga 3180
gttagtaggc cccggggaga cagagtctgc acaggccctt tctggggcca cctccatcca 3240
cgaggagcag cctgagcctt ggtggccgaa ccttgaccgt cccggagcac agcttcaggg 3300
cagggaaccg gagcccctgg ggggcctcac gggtgtgacg aggcccttca ttgcaggcag 3360
gtgggccaat gggagccctc acccacgcaa gccgagacac cacccagagt gcaggctgcc 3420
tggccccttc tggcacggcc agctccacac cccctgccta gggtatgtgt ggtcctaagg 3480
gctaggagct tcccctacta acatctccca gaaaaagcag ttaagcccct cagggcacag 3540
caaggttaga cacagccccc atccccagat caggactcca tcttgctaag tggcatcacc 3600
gtcaccagcc tccccttatt taaaagcagc gactggtgtt gccgcaggta cctggtctac 3660
gaagacgcag gcatccctct cccaccgtcc acctccccgg gggccgctga cagcacagtc 3720
gcctgggtgc acgcttgtgg gggcagcagg aacggggctg tcggctctca ggggatctgg 3780
ctgcagccag ggcgagggcc tggcccttcc ttccagctcc ttccggctcc ttccagctga 3840
agggcaggaa gctctggccg cttagcttct agggttccat ctccctagaa aggtgcccac 3900
gcccagggca tcagtcagta gcggcagcag cagcagactc ggggctttcc cagggtggcg 3960
cagccacccc agctgcatgt cacctcagct ctccatctta ttgccatttt gtagatgagg 4020
aagctgagac cagaaaggct aagacccatg ccccaggcac cacacccatc tcttgggggc 4080
tgggcacctg ctacccgagg ccacctcctg aagcccccac tcttccccca tgttccactt 4140
caggagccgc gggggcccat cctgacaccc ggggttcctc agcccagcgc agatgtgctt 4200
cagttccaga gggcttgttg atttgtttct taggtacgtt acctgtccac cctgagtcca 4260
gtgaggctgt cccaagagcc cctgtagtgt gctcctggga agggctgggg gggctggggg 4320
ggctgggaga ggcccagggg cagctgtcac tggaacccca gccagatgtc caaggaagcc 4380
ggccagaaca cggagcagcc agatggcccc agctgcacct gtctagggag cccatgcagc 4440
ctccttgcac tggagaagca gctgtgaaag tagacagagt tgagacttcg ccgtggtcag 4500
gagaaaatgc aaattcccag gaacaagaat cctttaagtg atatgttttt ataaaactaa 4560
acaaatcaac aaataaatct tgaaggcgga tggttttccc agcagtgcag gggttggagg 4620
gaggctgctg gcactcctgg ggccaagggg gacaggcagt ggtcctgagt ctgctcagag 4680
aggcaaggca gaaggagctc gccaggcagg tcagctcaca tctgtccaag tcgctctggt 4740
cagaaacagc gactctcccc cattccccca gcgttcccac caggcctggg ctgctgggaa 4800
gcccttgctg tacccaggag cccgacccgc agtatcctgg cacagagcca cttgtcactc 4860
agaacagtca gtgtctccaa cgcacaaaca tccactcctc tgttaccagt taaagcactt 4920
taatgcttta aggtgaaaac gaaatcccat ccgtgttttt cgtgtaagat cgtgcttctc 4980
cgagcagtat taatggacgc cctccaatga cataacaact gtttttggta atgtaatctt 5040
gggaaaatgt gttatttttt tagctgtgtt tcagtgggga tttttgtttt tgtaacataa 5100
taaagtgtat gttccaatga aaaaaaaaaa a 5131
<210> 10
<211> 1395
<212> DNA
<213>
Claims (11)
(b) 상기 (a) 단계에서 측정한 유전자의 발현 수준 또는 메틸화 수준을 정상 대조군 샘플의 동일 유전자의 발현 수준 또는 메틸화 수준과 비교하는 단계를 포함하는, 건선 진단에 필요한 정보를 제공하는 방법.
(a) a gene selected from the group consisting of the TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9, the FANK1 gene represented by the nucleotide sequence of SEQ ID NO: 10, and the PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: 11 from the biological sample of the subject Measuring the expression level or methylation level of one gene; And
(b) comparing the expression level or methylation level of the gene measured in step (a) with an expression level or methylation level of the same gene in a normal control sample.
The method according to claim 1, wherein the expression level is measured by RT-PCR, competitive RT-PCR, real-time RT-PCR, RNase protection assay, Northern blotting, DNA microarray chip, Western blotting, enzyme-linked immunosorbent assay, radioimmunoassay (RIA), radial immunodiffusion, Ouchteroni Wherein the method is selected from the group consisting of immunodiffusion, rocket immunoelectrophoresis, immunohistochemistry, immunoprecipitation, complement fixation, flow cytometry (FACS) and protein chip methods.
The method according to claim 1, wherein the methylation level is measured by MIRA (methylated-CpG island recovery assay), PCR, methylation specific PCR, real time methylation specific PCR, Characterized in that it is measured by at least one method selected from the group consisting of PCR using an antigen binding protein, quantitative PCR, pyrosequencing and bisulfite sequencing.
2. The method of claim 1, wherein the biological sample is at least one selected from the group consisting of blood, urine, cells and tissues.
5. The method of claim 4, wherein the cell is a CD4 + T cell.
HOXA5(GenBank Accession No. NM_019102), TPTE (GenBank Accession No. NM_199260), SPESP1(GenBank Accession No. NM_145658), MIR200A(GenBank Accession No. NR_029834), NADK(GenBank Accession No. NM_001198995), LOC100130417(GenBank Accession No. NR_026874), MIR663B(GenBank Accession No. NR_031608), ANKRD30BL(GenBank Accession No. NR_027020), UCN(GenBank Accession No. NM_003353), LOC100130872(GenBank Accession No. NR_024569), SPON2(GenBank Accession No. NM_001199021), MIR1229(GenBank Accession No. NR_031598), C6orf201(GenBank Accession No. NM_001085401), MEST(GenBank Accession No. NM_002402), SOHLH1(GenBank Accession No. NM_001101677), SYCE1(GenBank Accession No. NM_001143763), ANKRD30A(GenBank Accession No. NM_052997), KCNQ1DN(GenBank Accession No. NR_024627), AGAP2(GenBank Accession No. NM_001122772), TDRD9(GenBank Accession No. NM_153046), FAM181A(GenBank Accession No. NM_001207074), KLHL33(GenBank Accession No. NM_001109997), REREP3(GenBank Accession No. NR_033735), NOX5(GenBank Accession No. NR_033671), NCRNA00273(GenBank Accession No. NR_038368), ALOX12(GenBank Accession No. NM_000697), MIR3187(GenBank Accession No. NR_036154), LOC100288123(GenBank Accession No. NR_034114), EXOC3L2(GenBank Accession No. NM_138568), MIR4745(GenBank Accession No. NR_039900), C19orf77(GenBank Accession No. NM_001136503), C19orf34(GenBank Accession No. NR_033400), MIR663(GenBank Accession No. NR_030386), C20orf177(GenBank Accession No. NM_001190826), GNAS(GenBank Accession No. NR_003259), TP73(GenBank Accession No. NM_001126240), TTLL10(GenBank Accession No. NM_153254), FAM132A(GenBank Accession No. NM_001014980), C1orf146(GenBank Accession No. NM_001012425), EIF2B3(GenBank Accession No. NM_020365), CCDC27(GenBank Accession No. NM_152492), CROCCL1(GenBank Accession No. NR_026752), FAM58B(GenBank Accession No. NM_001105517), TMEM61(GenBank Accession No. NM_182532), OBSCN(GenBank Accession No. NM_052843), OBSCN(GenBank Accession No. NM_001098623), GPR25(GenBank Accession No. NM_005298), C1orf170(GenBank Accession No. NR_027693), FGR(GenBank Accession No. NM_005248), HSPA7(GenBank Accession No. NR_024151), PER3(GenBank Accession No. NM_016831), CLDN19(GenBank Accession No. NM_001123395), MMEL1(GenBank Accession No. NM_033467), PLEKHN1(GenBank Accession No. NM_032129), GPR37L1(GenBank Accession No. NM_004767), SLC25A44(GenBank Accession No. NM_014655), ICMT(GenBank Accession No. NM_012405), KLF17(GenBank Accession No. NM_173484), AFARP1(GenBank Accession No. NR_002796), HIST3H3(GenBank Accession No. NM_003493), OR2L13(GenBank Accession No. NM_175911), PVRL4(GenBank Accession No. NM_030916), EPS8L3(GenBank Accession No. NM_139053), CLCNKA(GenBank Accession No. NM_004070), NCRNA00164(GenBank Accession No. NR_027020), UCN(GenBank Accession No. NM_003353), KRTCAP3(GenBank Accession No. NM_173853), NCRNA00164(GenBank Accession No. NR_027019), ANKMY1(GenBank Accession No. NM_016552), TEKT4(GenBank Accession No. NM_144705), LOC654433(GenBank Accession No. NR_015377), DNAJC5G(GenBank Accession No. NM_173650), C2orf54(GenBank Accession No. NM_001085437), ALPPL2(GenBank Accession No. NM_031313), KLHL30(GenBank Accession No. NM_198582), POTEF(GenBank Accession No. NM_001099771), BOLL(GenBank Accession No. NM_033030), RGPD4(GenBank Accession No. NM_182588), TUBA3D(GenBank Accession No. NM_080386), ARHGEF4(GenBank Accession No. NM_032995), RGPD3(GenBank Accession No. NM_001144013), CRYGA(GenBank Accession No. NM_014617), PRLH(GenBank Accession No. NM_015893), LOC401010(GenBank Accession No. NR_002826), MFSD2B(GenBank Accession No. NM_001080473), EMILIN1(GenBank Accession No. NM_007046), SCTR(GenBank Accession No. NM_002980), C2orf39(GenBank Accession No. NM_145038), NT5DC2(GenBank Accession No. NM_022908), PRR23C(GenBank Accession No. NM_001134657), ITIH4(GenBank Accession No. NM_002218), DPPA2(GenBank Accession No. NM_138815), RARRES1(GenBank Accession No. NM_206963), GRK7(GenBank Accession No. NM_139209), TM4SF19(GenBank Accession No. NM_138461), OSTalpha(GenBank Accession No. NM_152672), AMT(GenBank Accession No. NM_000481), PRSS50(GenBank Accession No. NM_013270), HTR3E(GenBank Accession No. NM_182589), EIF4E3(GenBank Accession No. NM_173359), PLXNA1(GenBank Accession No. NM_032242), DAZL(GenBank Accession No. NM_001351), PRR23A(GenBank Accession No. NM_001134659), SLC6A11(GenBank Accession No. NM_014229), PRSS42(GenBank Accession No. NM_182702), LOC100130872(GenBank Accession No. NR_024569), DCAF4L1(GenBank Accession No. NM_001029955), C4orf44(GenBank Accession No. NM_001042690), TRIM60(GenBank Accession No. NM_152620), FAM92A3(GenBank Accession No. NR_003612), ADAD1(GenBank Accession No. NM_139243), RBM46(GenBank Accession No. NM_144979), OTOP1(GenBank Accession No. NM_177998), SLC26A1(GenBank Accession No. NM_213613), RNF212(GenBank Accession No. NM_001131034), LOC650293(GenBank Accession No. NM_001040071), ZNF595(GenBank Accession No. NM_182524), FRG1(GenBank Accession No. NM_004477), YTHDC1(GenBank Accession No. NM_001031732), NAP1L5(GenBank Accession No. NM_153757), COX7B2(GenBank Accession No. NM_130902), FTMT(GenBank Accession No. NM_177478), LRRC14B(GenBank Accession No. NM_001080478), SLC25A2(GenBank Accession No. NM_031947), CMYA5(GenBank Accession No. NM_153610), SLC6A19(GenBank Accession No. NM_001003841), IL3(GenBank Accession No. NM_000588), C5orf47(GenBank Accession No. NM_001144954), DND1(GenBank Accession No. NM_194249), CDX1(GenBank Accession No. NM_001804), SLC45A2(GenBank Accession No. NM_016180), CDH9(GenBank Accession No. NM_016279), FAM170A(GenBank Accession No. NM_182761), PDLIM4(GenBank Accession No. NM_003687), PFN3(GenBank Accession No. NM_001029886), ZDHHC11(GenBank Accession No. NM_024786), LOC134466(GenBank Accession No. NR_026867), PPP1R2P3(GenBank Accession No. NR_002168), GMCL1L(GenBank Accession No. NR_003281), PLEKHG4B(GenBank Accession No. NM_052909), IRX2(GenBank Accession No. NM_033267), C6orf201(GenBank Accession No. NM_001085401), HIST1H1A(GenBank Accession No. NM_005325), DUSP22(GenBank Accession No. NM_020185), HDGFL1(GenBank Accession No. NM_138574), DDX43(GenBank Accession No. NM_018665), PLAGL1(GenBank Accession No. NM_006718), HIST1H4G(GenBank Accession No. NM_003547), DPPA5(GenBank Accession No. NM_001025290), FAM50B(GenBank Accession No. NM_012135), FRMD1(GenBank Accession No. NM_024919), PNLDC1(GenBank Accession No. NM_173516), TDRD6(GenBank Accession No. NM_001010870), HUS1B(GenBank Accession No. NM_148959), ID4(GenBank Accession No. NM_001546), MCART3P(GenBank Accession No. NR_026540), C6orf221(GenBank Accession No. NM_001017361), MEST(GenBank Accession No. NM_002402), BHLHA15(GenBank Accession No. NM_177455), NOBOX(GenBank Accession No. NM_001080413), HOXA4(GenBank Accession No. NM_002141), GPR146(GenBank Accession No. NM_138445), ZNF716(GenBank Accession No. NM_001159279), RAMP3(GenBank Accession No. NM_005856), AMZ1(GenBank Accession No. NM_133463), SGCE(GenBank Accession No. NM_001099401), ELFN1(GenBank Accession No. NM_001128636), CPA1(GenBank Accession No. NM_001868), AMAC1L2(GenBank Accession No. NM_054028), TSPYL5(GenBank Accession No. NM_033512), KIAA1875(GenBank Accession No. NR_024207), DCAF4L2(GenBank Accession No. NM_152418), SLC39A4(GenBank Accession No. NM_017767), HTRA4(GenBank Accession No. NM_153692), POTEA(GenBank Accession No. NM_001005365), PTP4A3(GenBank Accession No. NM_032611), CSMD3(GenBank Accession No. NM_198124), NRBP2(GenBank Accession No. NM_178564), LOC100130274(GenBank Accession No. NM_001162914), C8orf73(GenBank Accession No. NM_001100878), GPIHBP1(GenBank Accession No. NM_178172), LY6D(GenBank Accession No. NM_003695), GPT(GenBank Accession No. NM_005309), MAPK15(GenBank Accession No. NM_139021), LRRC24(GenBank Accession No. NM_001024678), RP1L1(GenBank Accession No. NM_178857), SLC45A4(GenBank Accession No. NM_001080431), SNX16(GenBank Accession No. NM_022133), SOHLH1(GenBank Accession No. NM_001012415), EGFL7(GenBank Accession No. NM_016215), PTGDS(GenBank Accession No. NM_000954), NPR2(GenBank Accession No. NM_003995), DBH(GenBank Accession No. NM_000787), NR5A1(GenBank Accession No. NM_004959), FAM166A(GenBank Accession No. NM_001001710), C9orf135(GenBank Accession No. NM_001010940), MAMDC4(GenBank Accession No. NM_206920), CARD9(GenBank Accession No. NM_052813), OR13J1(GenBank Accession No. NM_001004487), C9orf152(GenBank Accession No. NM_001012993), POMT1(GenBank Accession No. NM_001136113), TMC1(GenBank Accession No. NM_138691), CACNA1B(GenBank Accession No. NM_000718), PRKACG(GenBank Accession No. NM_002732), PAEP(GenBank Accession No. NM_001018049), S1PR3(GenBank Accession No. NM_005226), SNORD62A(GenBank Accession No. NR_002914), ANKRD30A(GenBank Accession No. NM_052997), C10orf116(GenBank Accession No. NM_006829), GPR26(GenBank Accession No. NM_153442), CTBP2(GenBank Accession No. NM_022802), CCNY(GenBank Accession No. NM_181698), PNLIPRP2(GenBank Accession No. NM_005396), PYROXD2(GenBank Accession No. NM_032709), GDF2(GenBank Accession No. NM_016204), MMP21(GenBank Accession No. NM_147191), CALML3(GenBank Accession No. NM_005185), JAKMIP3(GenBank Accession No. NM_001105521), ANKRD2(GenBank Accession No. NM_020349), C10orf108(GenBank Accession No. NR_027152), IDI2(GenBank Accession No. NM_033261), RBP3(GenBank Accession No. NM_002900), TUBB8(GenBank Accession No. NM_177987), TUBGCP2(GenBank Accession No. NM_006659), KCNQ1DN(GenBank Accession No. NR_024627), LOC441601(GenBank Accession No. NR_003034), SPDYC(GenBank Accession No. NM_001008778), CD248(GenBank Accession No. NM_020404), TSSC4(GenBank Accession No. NM_005706), H19(GenBank Accession No. NR_002196), LDHAL6A(GenBank Accession No. NM_144972), FOXR1(GenBank Accession No. NM_181721), PKP3(GenBank Accession No. NM_007183), MS4A15(GenBank Accession No. NM_001098835), MRGPRE(GenBank Accession No. NM_001039165), MUC6(GenBank Accession No. NM_005961), LSP1(GenBank Accession No. NM_002339), TNNT3(GenBank Accession No. NM_006757), TP53AIP1(GenBank Accession No. NM_022112), CATSPER1(GenBank Accession No. NM_053054), TAGLN(GenBank Accession No. NM_001001522), CABP2(GenBank Accession No. NM_016366), GNG3(GenBank Accession No. NM_012202), CEND1(GenBank Accession No. NM_016564), FOLR3(GenBank Accession No. NM_000804), TMEM218(GenBank Accession No. NM_001080546), TBX10(GenBank Accession No. NM_005995), SCGB2A1(GenBank Accession No. NM_002407), C11orf36(GenBank Accession No. NR_027138), DRD4(GenBank Accession No. NM_000797), MUC2(GenBank Accession No. NM_002457), AGAP2(GenBank Accession No. NM_001122772), RPL13AP20(GenBank Accession No. NR_003932), FIGNL2(GenBank Accession No. NM_001013690), ACRBP(GenBank Accession No. NM_032489), SLC6A12(GenBank Accession No. NM_003044), KRT3(GenBank Accession No. NM_057088), TUBGCP3(GenBank Accession No. NM_006322), SOHLH2(GenBank Accession No. NM_017826), ATP4B(GenBank Accession No. NM_000705), RNF17(GenBank Accession No. NM_031277), TUBA3C(GenBank Accession No. NM_006001), CSNK1A1L(GenBank Accession No. NM_145203), DLEU7(GenBank Accession No. NM_198989), TDRD9(GenBank Accession No. NM_153046), DIO3(GenBank Accession No. NM_001362), COX8C(GenBank Accession No. NM_182971), ASPG(GenBank Accession No. NM_001080464), MGC23270(GenBank Accession No. NR_024396), RPL13AP3(GenBank Accession No. NR_004844), RPS6KL1(GenBank Accession No. NM_031464), ACOT4(GenBank Accession No. NM_152331), CMTM5(GenBank Accession No. NM_138460), INF2(GenBank Accession No. NM_022489), AMN(GenBank Accession No. NM_030943), ABHD12B(GenBank Accession No. NM_181533), TBPL2(GenBank Accession No. NM_199047), PSMB11(GenBank Accession No. NM_001099780), CATSPER2(GenBank Accession No. NM_054020), LOC390594(GenBank Accession No. NM_001101362), C15orf2(GenBank Accession No. NM_018958), PCSK6(GenBank Accession No. NM_002570), C15orf60(GenBank Accession No. NM_001042367), SNORD115-6(GenBank Accession No. NR_003298), SNORD115-17(GenBank Accession No. NR_003309), RASL12(GenBank Accession No. NM_016563), SNORD115-32(GenBank Accession No. NR_003347), SNORD115-31(GenBank Accession No. NR_003346), LASS3(GenBank Accession No. NM_178842), SNORD115-37(GenBank Accession No. NR_003352), LDHAL6B(GenBank Accession No. NM_033195), GABRB3(GenBank Accession No. NM_000814), SNORD115-25(GenBank Accession No. NR_003342), SLC28A2(GenBank Accession No. NM_004212), ZNF469(GenBank Accession No. NM_001127464), CCDC154(GenBank Accession No. NM_001143980), TESSP1(GenBank Accession No. NM_001135086), ELMO3(GenBank Accession No. NM_024712), ZSCAN10(GenBank Accession No. NM_032805), PDIA2(GenBank Accession No. NM_006849), LOC146336(GenBank Accession No. NR_027242), CLDN9(GenBank Accession No. NM_020982), CLDN6(GenBank Accession No. NM_021195), IGFALS(GenBank Accession No. NM_001146006), IL34(GenBank Accession No. NM_152456), NAT15(GenBank Accession No. NM_001083601), SSTR5(GenBank Accession No. NM_001053), DNASE1L2(GenBank Accession No. NM_001374), MSLN(GenBank Accession No. NM_005823), CMTM1(GenBank Accession No. NM_052999), FBRS(GenBank Accession No. NM_001105079), ZNF597(GenBank Accession No. NM_152457), SLC5A11(GenBank Accession No. NM_052944), IL17C(GenBank Accession No. NM_013278), FAM18A(GenBank Accession No. NM_001079512), TPSG1(GenBank Accession No. NM_012467), GPR97(GenBank Accession No. NM_170776), PRM2(GenBank Accession No. NM_002762), JMJD8(GenBank Accession No. NM_001005920), ADAD2(GenBank Accession No. NM_139174), C16orf81(GenBank Accession No. NR_024347), TPSD1(GenBank Accession No. NM_012217), ADCY7(GenBank Accession No. NM_001114), ZG16B(GenBank Accession No. NM_145252), CHST5(GenBank Accession No. NM_024533), PRR25(GenBank Accession No. NM_001013638), ABCA3(GenBank Accession No. NM_001089), CCDC79(GenBank Accession No. NM_001136505), WDR59(GenBank Accession No. NM_030581), GLIS2(GenBank Accession No. NM_032575), MT1L(GenBank Accession No. NR_001447), TMPRSS8(GenBank Accession No. NR_026864), TMC7(GenBank Accession No. NM_024847), DNASE1(GenBank Accession No. NM_005223), ALOX12(GenBank Accession No. NM_000697), KCNAB3(GenBank Accession No. NM_004732), DYSFIP1(GenBank Accession No. NM_001007533), QRICH2(GenBank Accession No. NM_032134), FSCN2(GenBank Accession No. NM_012418), CACNG1(GenBank Accession No. NM_000727), TMEM88(GenBank Accession No. NM_203411), UTS2R(GenBank Accession No. NM_018949), HSPB9(GenBank Accession No. NM_033194), NLGN2(GenBank Accession No. NM_020795), FOXO3B(GenBank Accession No. NR_026718), FLJ36000(GenBank Accession No. NR_027084), RPH3AL(GenBank Accession No. NM_006987), GGT6(GenBank Accession No. NM_001122890), RAB34(GenBank Accession No. NM_031934), SHISA6(GenBank Accession No. NM_207386), GPR172B(GenBank Accession No. NM_001104577), SLFN13(GenBank Accession No. NM_144682), HSF5(GenBank Accession No. NM_001080439), ENPP7(GenBank Accession No. NM_178543), AIPL1(GenBank Accession No. NM_014336), AMAC1(GenBank Accession No. NM_152462), KCTD11(GenBank Accession No. NM_001002914), WSB1(GenBank Accession No. NM_015626), SERPINF1(GenBank Accession No. NM_002615), ULK2(GenBank Accession No. NM_014683), TBX4(GenBank Accession No. NM_018488), CCDC144NL(GenBank Accession No. NM_001004306), KCNG2(GenBank Accession No. NM_012283), RNF138(GenBank Accession No. NM_016271), ANKRD30B(GenBank Accession No. NM_001145029), PSMA8(GenBank Accession No. NM_144662), CNDP1(GenBank Accession No. NM_032649), EXOC3L2(GenBank Accession No. NM_138568), C19orf77(GenBank Accession No. NM_001136503), C19orf34(GenBank Accession No. NM_152771), FZR1(GenBank Accession No. NM_001136198), TMPRSS9(GenBank Accession No. NM_182973), ZNF558(GenBank Accession No. NM_144693), PLVAP(GenBank Accession No. NM_031310), YJEFN3(GenBank Accession No. NM_198537), CCDC155(GenBank Accession No. NM_144688), TMEM86B(GenBank Accession No. NM_173804), SPACA4(GenBank Accession No. NM_133498), PRR22(GenBank Accession No. NM_001134316), ELANE(GenBank Accession No. NM_001972), ACPT(GenBank Accession No. NM_033068), PSPN(GenBank Accession No. NM_004158), WDR88(GenBank Accession No. NM_173479), PLIN4(GenBank Accession No. NM_001080400), OR10H1(GenBank Accession No. NM_013940), CCDC105(GenBank Accession No. NM_173482), SNORD37(GenBank Accession No. NR_002602), DUS3L(GenBank Accession No. NM_020175), CBLC(GenBank Accession No. NM_012116), LGALS4(GenBank Accession No. NM_006149), COX7A1(GenBank Accession No. NM_001864), KCNA7(GenBank Accession No. NM_031886), NTN5(GenBank Accession No. NM_145807), SNORD35A(GenBank Accession No. NR_000018), FFAR2(GenBank Accession No. NM_005306), ZSCAN1(GenBank Accession No. NM_182572), LOC126536(GenBank Accession No. NR_026828), LYPD4(GenBank Accession No. NM_173506), DMRTC2(GenBank Accession No. NM_001040283), ACTL9(GenBank Accession No. NM_178525), TDRD12(GenBank Accession No. NM_001110822), CAPS(GenBank Accession No. NM_004058), PGLYRP1(GenBank Accession No. NM_005091), CAPN12(GenBank Accession No. NM_144691), FAM83E(GenBank Accession No. NM_017708), NLRP4(GenBank Accession No. NM_134444), PPAP2C(GenBank Accession No. NM_003712), UPK1A(GenBank Accession No. NM_007000), INSL3(GenBank Accession No. NM_005543), KCNJ14(GenBank Accession No. NM_170720), ODF3L2(GenBank Accession No. NM_182577), PLK5P(GenBank Accession No. NR_026557), AURKC(GenBank Accession No. NM_001015878), ECH1(GenBank Accession No. NM_001398), SRMS(GenBank Accession No. NM_080823), FRG1B(GenBank Accession No. NR_003579), SSTR4(GenBank Accession No. NM_001052), SLC12A5(GenBank Accession No. NM_020708), L3MBTL(GenBank Accession No. NM_032107), TCEA2(GenBank Accession No. NM_198723), FAM83C(GenBank Accession No. NM_178468), PHF20(GenBank Accession No. NM_016436), COX4I2(GenBank Accession No. NM_032609), CTCFL(GenBank Accession No. NM_080618), SALL4(GenBank Accession No. NM_020436), SLC13A3(GenBank Accession No. NM_022829), MYL9(GenBank Accession No. NM_006097), ADRA1D(GenBank Accession No. NM_000678), RTEL1(GenBank Accession No. NM_032957), BIRC7(GenBank Accession No. NM_139317), AIRE(GenBank Accession No. NM_000383), TFF1(GenBank Accession No. NM_003225), KRTAP10-6(GenBank Accession No. NM_198688), FTCD(GenBank Accession No. NM_006657), IGSF5(GenBank Accession No. NM_001080444), POTED(GenBank Accession No. NM_174981), PLAC4(GenBank Accession No. NM_182832), SNORA80(GenBank Accession No. NR_002996), MOV10L1(GenBank Accession No. NM_018995), HORMAD2(GenBank Accession No. NM_152510), LOC400931(GenBank Accession No. NR_027033), CACNA1I(GenBank Accession No. NM_021096), TMEM211(GenBank Accession No. NM_001001663), BAIAP2L2(GenBank Accession No. NM_025045), GSC2(GenBank Accession No. NM_005315), SUSD2(GenBank Accession No. NM_019601), GGT1(GenBank Accession No. NM_005265), RFPL2(GenBank Accession No. NM_001098527), MCHR1(GenBank Accession No. NM_005297), MAPK8IP2(GenBank Accession No. NM_012324), CHADL(GenBank Accession No. NM_138481), RGL4(GenBank Accession No. NM_153615), TCF20(GenBank Accession No. NM_005650), OTUD6A(GenBank Accession No. NM_207320), FAM9A(GenBank Accession No. NM_174951), RAB40AL(GenBank Accession No. NM_001031834), CT45A1(GenBank Accession No. NM_001017417), GJB1(GenBank Accession No. NM_000166), YY2(GenBank Accession No. NM_206923), FAM9B(GenBank Accession No. NM_205849)
The method according to claim 1, wherein the method further comprises the step of measuring an expression level or a methylation level of at least one gene selected from the group consisting of the following genes:
GenBank Accession No. NM_019102), TPTE (GenBank Accession No. NM_199260), SPESP1 (GenBank Accession No. NM_145658), MIR200A (GenBank Accession No. NR_029834), NADK (GenBank Accession No. NM_001198995), LOC100130417 , GenBank Accession No. NR_026074), MIR663B (GenBank Accession No. NR_031608), ANKRD30BL (GenBank Accession No. NR_027020), UCN (GenBank Accession No. NM_003353), LOC100130872 (GenBank Accession No. NR_024569), SPON2 (GenBank Accession No. NM_001199021), MIR1229 (GenBank Accession No. NR_031598), C6orf201 (GenBank Accession No. NM_001085401), MEST (GenBank Accession No. NM_002402), SOHLH1 (GenBank Accession No. NM_001101677), SYCE1 (GenBank Accession No. NM_001143763), ANKRD30A (GenBank Accession No. GenBank Accession No. NM_001209974), REREP3 (GenBank Accession No. NM_001109997), GenBank Accession No. NM_001109998, GenBank Accession No. NM_0299997), KCNQ1DN (GenBank Accession No. NR_024627), AGAP2 (GenBank Accession No. NM_001122772), TDRD9 (GenBank Accession No. NM_153046), FAM181A GenBank Accession No. NR_033735), NOX5 (GenBank Accession No. GenBank Accession No. NR_038678), ALOX12 (GenBank Accession No. NM_000697), MIR3187 (GenBank Accession No. NR_036154), LOC100288123 (GenBank Accession No. NR_034114), EXOC3L2 (GenBank Accession No. NM_138568), MIR4745 GenBank Accession No. NR_039900), C19orf77 (GenBank Accession No. NM_001136503), C19orf34 (GenBank Accession No. NR_033400), MIR663 (GenBank Accession No. NR_030386), C20orf177 (GenBank Accession No. NM_001190826), GNAS (GenBank Accession No. NR_003259 ), TP73 (GenBank Accession No. NM_001126240), TTLL10 (GenBank Accession No. NM_153254), FAM132A (GenBank Accession No. NM_001014980), C1orf146 (GenBank Accession No. NM_001012425), EIF2B3 (GenBank Accession No. NM_020365), CCDC27 Accession No. NM_152492), CROCCL1 (GenBank Accession No. NR_026752), FAM58B (GenBank Accession No. NM_001105517), TMEM61 (GenBank Accession No. NM_182532), OBSCN (GenBank Accession No. NM_052843), OBSCN (GenBank Accession No. NM_001098623) , GPR25 (GenBank Accession No. NM_005298), C1orf17 0 (GenBank Accession No. < / RTI > , GenBank Accession No. NM_005248), HSPA7 (GenBank Accession No. NR_024151), PER3 (GenBank Accession No. NM_016831), CLDN19 (GenBank Accession No. NM_001123395), MMEL1 (GenBank Accession No. NM_033467), PLEKHN1 GenBank Accession No. NM_032129), GPR37L1 (GenBank Accession No. NM_004767), SLC25A44 (GenBank Accession No. NM_014655), ICMT (GenBank Accession No. NM_012405), KLF17 (GenBank Accession No. NM_173484), AFARP1 ), HIST3H3 (GenBank Accession No. NM_003493), OR2L13 (GenBank Accession No. NM_175911), PVRL4 (GenBank Accession No. NM_030916), EPS8L3 (GenBank Accession No. NM_139053), CLCNKA (GenBank Accession No. NM_004070), NCRNA00164 Accession No. NR_027020), UCN (GenBank Accession No. NM_003353), KRTCAP3 (GenBank Accession No. NM_173853), NCRNA00164 (GenBank Accession No. NR_027019), ANKMY1 (GenBank Accession No. NM_016552), TEKT4 (GenBank Accession No. NM_144705) , LOC654433 (GenBank Accession No. NR_015377), DNAJC5G (GenBank Accession No. NM_173650) , C2OF54 (GenBank Accession No. GenBank Accession No. NM_031313), KLHL30 (GenBank Accession No. NM_198582), POTEF (GenBank Accession No. NM_001099771), BOLL (GenBank Accession No. NM_033030), RGPD4 (GenBank Accession No. NM_182588), TUBA3D GenBank Accession No. NM_080386), ARHGEF4 (GenBank Accession No. NM_032995), RGPD3 (GenBank Accession No. NM_001144013), CRYGA (GenBank Accession No. NM_014617), PRLH (GenBank Accession No. NM_015893), LOC401010 (GenBank Accession No. NR_002826 ), MFSD2B (GenBank Accession No. NM_001080473), EMILIN1 (GenBank Accession No. NM_007046), SCTR (GenBank Accession No. NM_002980), C2orf39 (GenBank Accession No. NM_145038), NT5DC2 (GenBank Accession No. NM_022908), PRR23C Accession No. NM_001134657), ITIH4 (GenBank Accession No. NM_002218), DPPA2 (GenBank Accession No. NM_138815), RARRES1 (GenBank Accession No. NM_206963), GRK7 (GenBank Accession No. NM_139209), TM4SF19 (GenBank Accession No. NM_138461) , OSTalpha (GenBank Accession No. NM_152672), AMT (GenBank Accession No. NM_00048 1), PRSS50 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_001134659), SLC6A11 (GenBank Accession No. NM_001134659), and GenBank Accession No. NM_023251) GenBank Accession No. NM_014229), PRSS42 (GenBank Accession No. NM_182702), LOC100130872 (GenBank Accession No. NR_024569), DCAF4L1 (GenBank Accession No. NM_001029955), C4orf44 (GenBank Accession No. NM_001042690), TRIM60 ), FAM92A3 (GenBank Accession No. NR_003612), ADAD1 (GenBank Accession No. NM_139243), RBM46 (GenBank Accession No. NM_144979), OTOP1 (GenBank Accession No. NM_177998), SLC26A1 (GenBank Accession No. NM_213613), RNF212 Accession No. NM_001131034), LOC650293 (GenBank Accession No. NM_001040071), ZNF595 (GenBank Accession No. NM_182524), FRG1 (GenBank Accession No. NM_004477), YTHDC1 (GenBank Accession No. NM_001031732), NAP1L5 (GenBank Accession No. NM_153757) , COX7B2 (GenBank Accession No. NM_130902), FTMT (GenBank Accessio n No. (GenBank Accession No. NM_001080478), SLC25A2 (GenBank Accession No. NM_031947), CMYA5 (GenBank Accession No. NM_153610), SLC6A19 (GenBank Accession No. NM_001003841), IL3 (GenBank Accession No. NM_000588), C5orf47 GenBank Accession No. NM_001144954), DND1 (GenBank Accession No. NM_194249), CDX1 (GenBank Accession No. NM_001804), SLC45A2 (GenBank Accession No. NM_016180), CDH9 (GenBank Accession No. NM_016279), FAM170A (GenBank Accession No. NM_182761 ), PDLIM4 (GenBank Accession No. NM_003687), PFN3 (GenBank Accession No. NM_001029886), ZDHHC11 (GenBank Accession No. NM_024786), LOC134466 (GenBank Accession No. NR_026867), PPP1R2P3 (GenBank Accession No. NR_002168), GMCL1L Accession No. NR_003281), PLEKHG4B (GenBank Accession No. NM_052909), IRX2 (GenBank Accession No. NM_033267), C6orf201 (GenBank Accession No. NM_001085401), HIST1H1A (GenBank Accession No. NM_005325), DUSP22 (GenBank Accession No. NM_020185) , HDGFL1 (GenBank Accession No. NM_138574), DDX43 (GenBank Accession No . (GenBank Accession No. NM_007471), HIST1H4G (GenBank Accession No. NM_003547), DPPA5 (GenBank Accession No. NM_001025290), FAM50B (GenBank Accession No. NM_012135), FRMD1 (GenBank Accession No. NM_024919), PNLDC1 GenBank Accession No. NM_171616), TDRD6 (GenBank Accession No. NM_001010870), HUS1B (GenBank Accession No. NM_148959), ID4 (GenBank Accession No. NM_001546), MCART3P (GenBank Accession No. NR_026540), C6orf221 (GenBank Accession No. NM_001017361 GenBank Accession No. NM_002402), BHLHA15 (GenBank Accession No. NM_177455), NOBOX (GenBank Accession No. NM_001080413), HOXA4 (GenBank Accession No. NM_002141), GPR146 (GenBank Accession No. NM_138445), ZNF716 Accession No. NM_001159279), RAMP3 (GenBank Accession No. NM_005856), AMZ1 (GenBank Accession No. NM_133463), SGCE (GenBank Accession No. NM_001099401), ELFN1 (GenBank Accession No. NM_001128636), CPA1 (GenBank Accession No. NM_001868) , AMAC1L2 (GenBank Accession No. NM_054028), TSPYL5 (GenBank Accession No. NM_0335 12), KIAA1875 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_032611), PSTEA (GenBank Accession No. NM_032611), and CSMD3 (GenBank Accession No. NM_032611). GenBank Accession No. NM_198124), NRBP2 (GenBank Accession No. NM_178564), LOC100130274 (GenBank Accession No. NM_001162914), C8orf73 (GenBank Accession No. NM_001100878), GPIHBP1 (GenBank Accession No. NM_178172), LY6D ), GPT (GenBank Accession No. NM_005309), MAPK15 (GenBank Accession No. NM_139021), LRRC24 (GenBank Accession No. NM_001024678), RP1L1 (GenBank Accession No. NM_178857), SLC45A4 (GenBank Accession No. NM_001080431), SNX16 Accession No. NM_022133), SOHLH1 (GenBank Accession No. NM_001012415), EGFL7 (GenBank Accession No. NM_016215), PTGDS (GenBank Accession No. NM_000954), NPR2 (GenBank Accession No. NM_003995) , NR5A1 (GenBank Accession No. NM_004959), FAM166A (GenBank Accession No. NM_00 1001710), C9orf135 (GenBank Accession No. < / RTI > GenBank Accession No. NM_001136113, GenBank Accession No. NM_001136113), TMC1 (GenBank Accession No. NM_001136113), MAMDC4 (GenBank Accession No. NM_001136113), CARD9 (GenBank Accession No. NM_052813), OR13J1 (GenBank Accession No. NM_001004487), C9orf152 GenBank Accession No. NM_138691), CACNA1B (GenBank Accession No. NM_000718), PRKACG (GenBank Accession No. NM_002732), PAEP (GenBank Accession No. NM_001018049), S1PR3 (GenBank Accession No. NM_005226), SNORD62A , GenBank Accession No. NM_052997), C10orf116 (GenBank Accession No. NM_006829), GPR26 (GenBank Accession No. NM_153442), CTBP2 (GenBank Accession No. NM_022802), CCNY (GenBank Accession No. NM_181698), PNLIPRP2 Accession No. NM_005396), PYROXD2 (GenBank Accession No. NM_032709), GDF2 (GenBank Accession No. NM_016204), MMP21 (GenBank Accession No. NM_147191), CALML3 (GenBank Accession No. NM_005185), JAKMIP3 (GenBank Accession No. NM_001105521) , ANKRD2 (GenBank Accession No. NM_020349), C10orf108 (GenBank Accession No. (GenBank Accession No. NM_033261), RBP3 (GenBank Accession No. NM_002900), TUBB8 (GenBank Accession No. NM_177987), TUBGCP2 (GenBank Accession No. NM_006659), KCNQ1DN (GenBank Accession No. NR_024627), LOC441601 GenBank Accession No. NR_003034), SPDYC (GenBank Accession No. NM_001008778), CD248 (GenBank Accession No. NM_020404), TSSC4 (GenBank Accession No. NM_005706), H19 (GenBank Accession No. NR_002196), LDHAL6A (GenBank Accession No. NM_144972 ), FOXR1 (GenBank Accession No. NM_181721), PKP3 (GenBank Accession No. NM_007183), MS4A15 (GenBank Accession No. NM_001098835), MRGPRE (GenBank Accession No. NM_001039165), MUC6 (GenBank Accession No. NM_005961), LSP1 Accession No. NM_002339), TNNT3 (GenBank Accession No. NM_006757), TP53AIP1 (GenBank Accession No. NM_022112), CATSPER1 (GenBank Accession No. NM_053054), TAGLN (GenBank Accession No. NM_001001522), CABP2 (GenBank Accession No. NM_016366) , GNG3 (GenBank Accession No. NM_012202), CEND1 (GenBank Accession No. NM_016564), FOLR3 GenBank Accession No. GenBank Accession No. NM_0005975), GenBank Accession No. NM_005995), SCGB2A1 (GenBank Accession No. NM_002407), C11orf36 (GenBank Accession No. NR_027138), DRD4 (GenBank Accession No. NM_000797), MUC2 GenBank Accession No. NM_002457), AGAP2 (GenBank Accession No. NM_001122772), RPL13AP20 (GenBank Accession No. NR_003932), FIGNL2 (GenBank Accession No. NM_001013690), ACRBP (GenBank Accession No. NM_032489), SLC6A12 ), KRT3 (GenBank Accession No. NM_057088), TUBGCP3 (GenBank Accession No. NM_006322), SOHLH2 (GenBank Accession No. NM_017826), ATP4B (GenBank Accession No. NM_000705), RNF17 (GenBank Accession No. NM_031277), TUBA3C Accession No. NM_006001), CSNK1A1L (GenBank Accession No. NM_145203), DLEU7 (GenBank Accession No. NM_198989), TDRD9 (GenBank Accession No. NM_153046), DIO3 (GenBank Accession No. NM_001362), COX8C (GenBank Accession No. NM_182971) , ASPG (GenBank Accession No. NM_001080464), MGC23270 (GenBank Accession No. NR_024396 ), RPL13AP3 (GenBank Accession No. GenBank Accession No. NM_031464), ACOT4 (GenBank Accession No. NM_152331), CMTM5 (GenBank Accession No. NM_138460), INF2 (GenBank Accession No. NM_022489), AMN (GenBank Accession No. NM_030943), ABHD12B GenBank Accession No. NM_181533), TBPL2 (GenBank Accession No. NM_199047), PSMB11 (GenBank Accession No. NM_001099780), CATSPER2 (GenBank Accession No. NM_054020), LOC390594 (GenBank Accession No. NM_001101362), C15orf2 (GenBank Accession No. NM_018958 GenBank Accession No. NR_003309, GenBank Accession No. NR_003309), RASL12 (GenBank Accession No. NM_016563), GenBank Accession No. NM_0016563, , SNORD115-32 (GenBank Accession No. NR_003347), SNORD115-31 (GenBank Accession No. NR_003346), LASS3 (GenBank Accession No. NM_178842), SNORD115-37 (GenBank Accession No. NR_003352), LDHAL6B (GenBank Accession No. NM_033195 ), GABRB3 (GenBank Accession No. NM_000814), SNORD115-25 (GenBank Accession No. NR_003342), SLC28A 2 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_0021212), ZNF469 (GenBank Accession No. NM_001127464), CCDC154 (GenBank Accession No. NM_001143980), TESSP1 (GenBank Accession No. NM_001135086), ELMO3 (GenBank Accession No. NM_024712), ZSCAN10 GenBank Accession No. NM_006849), LOC146336 (GenBank Accession No. NR_027242), CLDN9 (GenBank Accession No. NM_020982), CLDN6 (GenBank Accession No. NM_021195), IGFALS (GenBank Accession No. NM_001146006), IL34 (GenBank Accession No. NM_152456 , GenBank Accession No. NM_001083601), SSTR5 (GenBank Accession No. NM_001053), DNASE1L2 (GenBank Accession No. NM_001374), MSLN (GenBank Accession No. NM_005823), CMTM1 (GenBank Accession No. NM_052999), FBRS Accession No. NM_001105079), ZNF597 (GenBank Accession No. NM_152457), SLC5A11 (GenBank Accession No. NM_052944), IL17C (GenBank Accession No. NM_013278), FAM18A (GenBank Accession No. NM_001079512), TPSG1 (GenBank Accession No. NM_012467) , GPR97 (GenBank Accession No. NM_170776), PRM2 (GenBank Accession No. NM_00 2762), JMJD8 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_139174), C16orf81 (GenBank Accession No. NR_024347), TPSD1 (GenBank Accession No. NM_012217), ADCY7 (GenBank Accession No. NM_001114), ZG16B (GenBank Accession No. NM_145252), CHST5 GenBank Accession No. NM_024533), PRR25 (GenBank Accession No. NM_001013638), ABCA3 (GenBank Accession No. NM_001089), CCDC79 (GenBank Accession No. NM_001136505), WDR59 (GenBank Accession No. NM_030581), GLIS2 (GenBank Accession No. NM_032575 ), MT1L (GenBank Accession No. NR_001447), TMPRSS8 (GenBank Accession No. NR_026864), TMC7 (GenBank Accession No. NM_024847), DNASE1 (GenBank Accession No. NM_005223), ALOX12 (GenBank Accession No. NM_000697), KCNAB3 Accession No. NM_004732), DYSFIP1 (GenBank Accession No. NM_001007533), QRICH2 (GenBank Accession No. NM_032134), FSCN2 (GenBank Accession No. NM_012418), CACNG1 (GenBank Accession No. NM_000727), TMEM88 (GenBank Accession No. NM_203411) , UTS2R (GenBank Accession No. NM_018949), HSPB9 (GenBank Accession No. NM_033194), NLGN 2 (GenBank Accession No. < / RTI > GenBank Accession No. NR_026718), FLJ36000 (GenBank Accession No. NR_027084), RPH3AL (GenBank Accession No. NM_006987), GGT6 (GenBank Accession No. NM_001122890), RAB34 (GenBank Accession No. NM_031934), SHISA6 GenBank Accession No. NM_207386), GPR172B (GenBank Accession No. NM_001104577), SLFN13 (GenBank Accession No. NM_144682), HSF5 (GenBank Accession No. NM_001080439), ENPP7 (GenBank Accession No. NM_178543), AIPL1 (GenBank Accession No. NM_014336 ), AMAC1 (GenBank Accession No. NM_152462), KCTD11 (GenBank Accession No. NM_001002914), WSB1 (GenBank Accession No. NM_015626), SERPINF1 (GenBank Accession No. NM_002615), ULK2 (GenBank Accession No. NM_014683), TBX4 Accession No. NM_018488), CCDC144NL (GenBank Accession No. NM_001004306), KCNG2 (GenBank Accession No. NM_012283), RNF138 (GenBank Accession No. NM_016271), ANKRD30B (GenBank Accession No. NM_001145029), PSMA8 (GenBank Accession No. NM_144662) , CNDP1 (GenBank Accession No. NM_032649), EXOC3L2 (GenBank Accession No. NM_1 38568), C19orf77 (GenBank Accession No. < / RTI > (GenBank Accession No. NM_031310), YJEFN3 (GenBank Accession No. NM_031310), GenBank Accession No. NM_031310, GenBank Accession No. NM_031310) GenBank Accession No. NM_198537), CCDC155 (GenBank Accession No. NM_144688), TMEM86B (GenBank Accession No. NM_173804), SPACA4 (GenBank Accession No. NM_133498), PRR22 (GenBank Accession No. NM_001134316), ELANE ), ACPT (GenBank Accession No. NM_033068), PSPN (GenBank Accession No. NM_004158), WDR88 (GenBank Accession No. NM_173479), PLIN4 (GenBank Accession No. NM_001080400), OR10H1 (GenBank Accession No. NM_013940), CCDC105 Accession No. NM_173482), SNORD37 (GenBank Accession No. NR_002602), DUS3L (GenBank Accession No. NM_020175), CBLC (GenBank Accession No. NM_012116), LGALS4 (GenBank Accession No. NM_006149), COX7A1 (GenBank Accession No. NM_001864) , KCNA7 (GenBank Accession No. NM_031886), NTN5 (GenBank Accession No. NM_145807), SN ORD35A (GenBank Accession No. < / RTI > GenBank Accession No. NM_005306), ZSCAN1 (GenBank Accession No. NM_182572), LOC126536 (GenBank Accession No. NR_026828), LYPD4 (GenBank Accession No. NM_173506), DMRTC2 (GenBank Accession No. NM_001040283), ACTL9 GenBank Accession No. NM_178525), TDRD12 (GenBank Accession No. NM_001110822), CAPS (GenBank Accession No. NM_004058), PGLYRP1 (GenBank Accession No. NM_005091), CAPN12 (GenBank Accession No. NM_144691), FAM83E (GenBank Accession No. NM_017708 ), NLRP4 (GenBank Accession No. NM_134444), PPAP2C (GenBank Accession No. NM_003712), UPK1A (GenBank Accession No. NM_007000), INSL3 (GenBank Accession No. NM_005543), KCNJ14 (GenBank Accession No. NM_170720), ODF3L2 Accession No. NM_182577), PLK5P (GenBank Accession No. NR_026557), AURKC (GenBank Accession No. NM_001015878), ECH1 (GenBank Accession No. NM_001398), SRMS (GenBank Accession No. NM_080823), FRG1B (GenBank Accession No. NR_003579) , SSTR4 (GenBank Accession No. NM_001052), SLC12A5 (GenBank Accession No. NM_020708), L3MBTL (GenBank Accession No. 2). (GenBank Accession No. NM_032609), CTCFL (GenBank Accession No. NM_080618), SALL4 (GenBank Accession No. NM_032107), TCEA2 (GenBank Accession No. NM_198723), FAM83C (GenBank Accession No. NM_178468), PHF20 (GenBank Accession No. NM_016436), COX4I2 GenBank Accession No. NM_020436), SLC13A3 (GenBank Accession No. NM_022829), MYL9 (GenBank Accession No. NM_006097), ADRA1D (GenBank Accession No. NM_000678), RTEL1 (GenBank Accession No. NM_032957), BIRC7 (GenBank Accession No. NM_139317 ), AIRE (GenBank Accession No. NM_000383), TFF1 (GenBank Accession No. NM_003225), KRTAP10-6 (GenBank Accession No. NM_198688), FTCD (GenBank Accession No. NM_006657), IGSF5 (GenBank Accession No. NM_001080444) (GenBank Accession No. NM_174981), PLAC4 (GenBank Accession No. NM_182832), SNORA80 (GenBank Accession No. NR_002996), MOV10L1 (GenBank Accession No. NM_018995), HORMAD2 (GenBank Accession No. NM_152510), LOC400931 (GenBank Accession No. CAMNA1I (GenBank Accession No. NM_021096), TMEM211 (GenBank Accession No. NM_001001663), BAI AP2L2 (GenBank Accession No. < / RTI > GenBank Accession No. NM_005297), SUSD2 (GenBank Accession No. NM_019601), GGT1 (GenBank Accession No. NM_005265), RFPL2 (GenBank Accession No. NM_001098527), MCHR1 (GenBank Accession No. NM_005297), MAPK8IP2 GenBank Accession No. NM_012324), CHADL (GenBank Accession No. NM_138481), RGL4 (GenBank Accession No. NM_153615), TCF20 (GenBank Accession No. NM_005650), OTUD6A (GenBank Accession No. NM_207320), FAM9A (GenBank Accession No. NM_174951 GenBank Accession No. NM_001031834), CT45A1 (GenBank Accession No. NM_001017417), GJB1 (GenBank Accession No. NM_000166), YY2 (GenBank Accession No. NM_206923), FAM9B (GenBank Accession No. NM_205849)
The expression level of any one gene selected from the group consisting of the TP73 gene represented by the nucleotide sequence of SEQ ID NO: 9, the FANK1 gene represented by the nucleotide sequence of SEQ ID NO: 10, and the PPAPDC3 gene represented by the nucleotide sequence of SEQ ID NO: A composition for the diagnosis of psoriasis comprising an agent for measuring the level.
8. The primer according to claim 7, wherein the agent for measuring the expression level of the gene specifically binds to the gene. A probe and an antibody specifically recognizing the expression protein of the gene.
9. The primer of claim 8, wherein the primer is any one or more primer pairs selected from the group consisting of primer pairs of SEQ ID NOS: 1 and 2, primer pairs of SEQ ID NOS: 3 and 4, and primer pairs of SEQ ID NOS: 5 and 6 Composition for the diagnosis of psoriasis.
8. The method according to claim 7, wherein the agent for measuring the methylation level is selected from the group consisting of a compound or a methylation-sensitive restriction enzyme that modifies an unmethylated cytosine base, a primer specific to the methylated sequence of the gene, and a primer specific to the unmethylated sequence Or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130041044A KR101490585B1 (en) | 2013-04-15 | 2013-04-15 | Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130041044A KR101490585B1 (en) | 2013-04-15 | 2013-04-15 | Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140123777A true KR20140123777A (en) | 2014-10-23 |
KR101490585B1 KR101490585B1 (en) | 2015-02-11 |
Family
ID=51994303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20130041044A KR101490585B1 (en) | 2013-04-15 | 2013-04-15 | Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101490585B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109735624A (en) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | Application of the gene marker in diagnosis of thyroid cancer |
CN115917010A (en) * | 2020-04-29 | 2023-04-04 | 台北医学大学 | Method for early detection, prediction of treatment response and prognosis of colorectal cancer |
WO2023063775A1 (en) * | 2021-10-15 | 2023-04-20 | 아주대학교산학협력단 | Use of mir-625-3p as biomarker for diagnosing severity of psoriasis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180044603A (en) * | 2016-10-24 | 2018-05-03 | (주)아모레퍼시픽 | Composition for diagnosing psoriasis-related diseases |
CN106868133A (en) * | 2017-02-24 | 2017-06-20 | 北京致成生物医学科技有限公司 | A kind of product for monitoring tumor development and its application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100953511B1 (en) * | 2009-12-28 | 2010-04-21 | (주)지노믹트리 | Diagnosis Kit and Chip for Psoriasis |
-
2013
- 2013-04-15 KR KR20130041044A patent/KR101490585B1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109735624A (en) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | Application of the gene marker in diagnosis of thyroid cancer |
CN115917010A (en) * | 2020-04-29 | 2023-04-04 | 台北医学大学 | Method for early detection, prediction of treatment response and prognosis of colorectal cancer |
WO2023063775A1 (en) * | 2021-10-15 | 2023-04-20 | 아주대학교산학협력단 | Use of mir-625-3p as biomarker for diagnosing severity of psoriasis |
Also Published As
Publication number | Publication date |
---|---|
KR101490585B1 (en) | 2015-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109790583B (en) | Methods for typing lung adenocarcinoma subtypes | |
KR101718940B1 (en) | Epigenetic early diagnostic composition for Alzheimer's disease or mild cognitive impairment | |
JP2009513125A (en) | Cancer detection method | |
JP2004505611A (en) | Methods, compositions, and kits for breast cancer detection and monitoring | |
KR101490585B1 (en) | Genetic Marker for Diagnosis of Psoriasis and Method for diagnosis of Psoriasis using the same | |
US20230105008A1 (en) | Methods and compositions for identifying castration resistant neuroendocrine prostate cancer | |
US20140005058A1 (en) | Methods and materials for the diagnosis of prostate cancers | |
KR20150067151A (en) | Method for screening cancer | |
CN110484621B (en) | Early warning method for liver cancer | |
WO2013052108A2 (en) | Methods and compositions for the treatment and diagnosis of ovarian cancer | |
JP4343705B2 (en) | Data collection method for estimating susceptibility to periodontal disease | |
CN106906290B (en) | CDSN as diagnosis and treatment target of tongue squamous cell carcinoma | |
KR101206028B1 (en) | Method for diagnosing a breast cancer using a breast cancer specific polymorphic sequence, polynucleotide specific to a breast cancer and microarray immobilized with the polynucleotide | |
EP3093343B1 (en) | Method for assessing lymph node metastatic potential of endometrial cancer | |
KR101985864B1 (en) | Composition for detecting Breast Cancer and Ovarian Cancer and uses thereof | |
KR100892587B1 (en) | Composition For Cancer diagnosis Containing Methylated Promoters of Colon Cancer Specific Expression-decreased Genes and Use Thereof | |
CN117813403A (en) | Method for disease detection | |
KR100894511B1 (en) | A multiplex RT-PCR primer, a composition and a kit comprising the same for diagnosing chronic Myeloid Leukemia | |
KR20060027893A (en) | Methylated promoters of colon cancer specific expression-decreased genes and use thereof | |
KR102085663B1 (en) | Method for providing information of prediction and diagnosis of small vessel occlusion using methylation level of WRB gene and composition therefor | |
CN105899675B (en) | Major histocompatibility complex single nucleotide polymorphisms | |
KR102085667B1 (en) | Method for providing information of prediction and diagnosis of small vessel occlusion using methylation level of GPR160 gene and composition therefor | |
CN107034270B (en) | CLIC3 as diagnosis and treatment target of lung adenocarcinoma | |
KR102158726B1 (en) | DNA methylation marker composition for diagnosis of delayed cerebral ischemia comprising intergenic region of ITPR3 gene upstream | |
KR102280575B1 (en) | Method for providing information of prediction and diagnosis of obesity using methylation level of GFI1 or ALOX5AP gene and composition therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190128 Year of fee payment: 5 |